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Zusammenfassung
Molekulare Mechanismen, die zu Veränderungen von Chromosomen-Telomeren führen,
spielen eine wesentliche Rolle bei der Entstehung chromosomaler Instabilität. Telom-
ere verkürzen sich mit jeder Zellteilung, was beim Erreichen einer kritischen Länge zu
replikativer Seneszenz oder Apoptose der Zelle führt. In Tumorzellen wird diese gegen
unbegrenztes Wachstum gerichtete Kontrolle durch Telomer-erhaltende Mechanismen
(engl.: Telomere Maintenance Mechanismen = TM-Mechanismen) aufgehoben. Zu den
bekannten TM-Mechanismen zählen die Telomerase-Aktivierung (TA) und der alterna-
tive Längenerhalt von Telomeren (ALT = Alternative lengthening of telomeres).
Primäres Ziel dieser Arbeit war die Bestimmung der Häuﬁgkeitsverteilung des TA- und
des ALT-Mechanismus in einem umfassenden Kollektiv an Weichteilsarkomen welches
in vorangegangenen Projekten, pathologisch, molekular-genetisch und klinisch eingehend
unter anderem hinsichtlich ihrer chromosomalen Veränderungen untersucht wurde. Ein
Schwerpunkt der hier beschriebenen Arbeit lag zunächst in der Etablierung der Metho-
den zur Detektion des ALT-Mechanismus. Die hierzu am häuﬁgsten verwendeten Marker
sind zum einen Kolokalisationen zwischen Telomeren und PML-Kernkörperchen (PML:
Promyelozytische Leukämie), auch ALT-assoziierte PML-Kernkörperchen (APBs) ge-
nannt, und zum anderen die Heterogenität in der Größe der Telomere mit dem zusät-
zlichen Auftreten von extrem großen Telomeren-Signalen. Hierzu wurde zunächst ein
Protokoll für eine kombinierte Telomere Fluoreszenz in situ Hybridisierung (Detektion:
Telomere) mit anschließender Immunﬂuoreszenz (Detektion: PML-Kernkörperchen) eta-
bliert. Für die in diesem Zusammenhang erstellten konfokalen Aufnahmen wurde ein
Programm zur automatischen Auswertung der Marker des ALT-Mechanism entwickelt.
Für die Bestimmung der Telomerase-Aktivität wurde das TRAP-Verfahren (Telomeric
Repeat Ampliﬁcation Protocol) verwendet. Diese Daten wurden anschließend vergle-
ichend mit den Daten der chromosomalen Veränderungen in Bezug gesetzt.
Die Studie sollte die Häuﬁgkeitsverteilung von TM-Mechanismen in Weichteilsark-
omen ermitteln und klären, ob diese mit speziﬁschen chromosomalen Imbalancen assozi-
iert sind. Die wichtigsten Ergebnisse dieser Arbeit lauten:
1. Das Auftreten der Telomer-erhaltenden Mechanismen ist stark von den einzelnen
Weichteilsarkom-Subtypen abhängig. Telomerase-Aktivität variiert von 100% in
synovialen Sarkomen bis hin zu 46% in pleomorphen Liposarkomen. Das Auftreten
der Marker die den ALT-Mechanismus charakterisieren, sind ebenso mit den ver-
schiedenen Weichteilsarkom-Subtypen assoziiert. Während in synovialen Sark-
omen keine sehr große Telomere-Signale detektiert werden konnten, liegt dieser
Anteil bei pleomorphen Liposarkomen bei 92%. Die Korrelation beider Telomer-
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erhaltenden Mechanismen hat ergeben, dass die Anzahl der Kolokalisationen zwis-
chen Telomeren und PML-Kernkörperchen als auch die der sehr großen Telomer-
Spots mit der Höhe Telomerase-Aktivität assoziiert ist.
2. Neben Tumorgewebe wurde in dieser Arbeit auch ein umfangreiches Kollektiv
von gesundem Gewebe auf Indikatoren des ALT Mechanismus untersucht. Die
Ergebnisse der automatischen Analyse zeigen im gesunden Gewebe ebenso wie
im Tumorgewebe das Auftreten von Kolokalisationen zwischen Telomeren und
PML-Kernkörperchen. Im Vergleich zu Tumorgewebe konnten jedoch in gesundem
Gewebe keine übergroßen Telomer-Spots detektiert werden. Diese Analyse stellt
APBs als quantitativen Marker für den ALT-Mechanismus in Frage. Das Auftreten
von sehr großen Telomere-Signalen wurde nur in Tumorgewebe gefunden wurde.
3. Die vergleichende genomische Hybridisierung (CGH) stellt einen Ansatz dar, mit
welchem ein robuster Nachweis von chromosomalen Imbalancen aufgezeigt werden
kann. Die Korrelation der CGH-Daten mit den Telomere-erhaltenden Mechanis-
men gibt keinen Hinweis darauf, dass bei einem der Mechanismen präferenziell
mehr chromosomale Imbalancen auftreten. Die Analyse hat jedoch ergeben, dass
Weichteilsarkome mit Telomerase-Aktivität ein diﬀerenziertes zytogenetisches Pro-
ﬁl gegenüber solchen Weichteilsarkomen mit Marker für den ALT-Mechanismus
aufweisen.
4. Im Rahmen diese Arbeit wurde für die automatische Quantiﬁzierung von Kolokali-
sationen aus konfokalen mikroskopischen Aufnahmen ein Computerprogramm en-
twickelt. Mittels dieses Programms können Indikatoren für den ALT Mechanismus
wie ALT-assoziierte PML Kernkörperchen und überdurchschnittlich große Telom-
ere detektiert werden. Die Detektion der verschiedenen Marker innerhalb des Zellk-
erns, wird über die Kernsegmentierung ermittelt. Mit Hilfe der vollautomatischen
Auswertung war es möglich über 500 konfokale mikroskopische Bilderstapel zu
analysieren und auszuwerten.
Die Charakterisierung von Tumoren spielt in der klinischen Diagnostik und in der
Beurteilung von Therapie-Entscheidungen eine wichtige Rolle. Mit dem Auftreten der
ALT-assoziierten PML-Kernkörperchen in gesundem Gewebe, muss in weiteren Studien
geklärt werden, wie stark diese spezielle Kernstruktur direkt mit dem ALT-Mechanismus
assoziiert ist. Die Charakterisierung von Telomere-erhaltenden Mechanismen und ihre
Rolle in der Tumorgenese könnten die Basis für neue gezielte therapeutische Ansätze
bilden.
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Abstract
Molecular mechanisms, which cause changes of the ends of chromosomes, the telomeres,
play an important role in the generation of genomic instability. In normal somatic
cells, the length of the telomeres are shortened during cell division due to the inability
of the cells to replicate their chromosome ends completely. Telomeres below a critical
length are dysfunctional and undergo apoptosis or permanent growth arrest referred to as
replicative senescence. One possibility to bypass telomere dysfunction and maintenance
of stable telomere length is the activation of a telomere maintenance mechanism. The
currently known telomere maintenance mechanisms in humans are telomerase activity
(TA-activity) and the alternative lengthening of telomeres (ALT-Mechanism).
The preliminary goal of the thesis was to assess the frequency distribution of the
activation of telomerase and of the ALT-mechanism in the major soft tissue sarcomas
subtypes, which had been genetically well characterized in preceding studies. A ﬁrst
step of the thesis was the establishment of a method to assess the ALT-mechanism. One
hallmark of ALT positive tumors/cells is the presence of ALT-associated promyelocytic
leukemia (PML) bodies (APBs). APBs are characterized by promyelocytic leukemia
(PML) bodies, which colocalize with telomeric DNA or telomere-speciﬁc binding pro-
teins. A further marker of ALT is their highly heterogeneous telomere length with some
exceptionally long telomeres. In order to assess ALT in human soft tissue sarcoma
subtypes by combined telomere ﬂuorescence in situ hybridization and PML immunoﬂuo-
rescence, confocal laser scanning microscope was used. 3D images were acquired, which
visualize telomere spots in the ﬁrst channel, PML bodies in the second channel and
DAPI stained nuclei in the third channel. The central task of image analysis was to
automatically detect and classify APBs within the cell nucleus as well as to detect and
quantify very large telomeres. Telomerase activity was evaluated by the TRAP assay
(telomeric repeat ampliﬁcation protocol). Afterwards, these data were correlated with
the number of chromosomal imbalances detected by comparative genomic hybridization
(CGH).
This study contributed to the understanding of the frequency distribution of telomere
maintenance mechanisms in soft tissue sarcoma subgroups and whether these mecha-
nisms are associated with speciﬁc chromosomal imbalances. The most important results
based on this thesis are:
1. The study demonstrates that the occurrence of the telomere maintenance mech-
anism is characteristic for the subtype of soft tissue sarcoma. The presence of
telomerase activity ranges from 100% in synovial sarcoma to 46% in pleomorphic
liposarcomas. The frequency of the marker for the ALT mechanism depends on
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the subtype of soft tissue sarcoma. While the telomeres detected in synovial sar-
comas were equal in length, 92% of all cases of pleomorphic liposarcomas showed
exceptionally long telomere signals. Furthermore, the correlation of both telomere
maintenance mechanisms has shown that in tumors with high telomerase activity,
the markers for the ALT-mechanism are signiﬁcantly reduced.
2. In order to investigated an abundant number of healthy tissue with regard to mark-
ers for the ALT mechanism automatic quantiﬁcation were performed. Healthy
tissue, as well as our investigated tumor samples, show the appearance of ALT-
associated PML bodies, whereas no telomeres with heterogeneous size and excep-
tionally long telomeres could be detected in healthy tissue. Therefore an important
questions remains: how tightly are APBs linked to the ALT mechanism?
3. Comparative genomic hybridization (CGH) allows for a genome-wide screen for
chromosomal imbalances in tumor samples. The correlation of the CGH data
and the telomere maintenance mechanisms revealed that tumors with telomerase
activity show a diﬀerent cytogenetic proﬁle compared to those tumors with markers
for ALT. In respect to the frequency of chromosomal imbalances, such as gains and
losses, there were no diﬀerences between both telomere maintenance mechanisms.
4. A new approach for an automated quantiﬁcation of telomere and PML spots as
well as colocalization in multi-channel 3D microscopy images to assess the ALT
mechanism were developed. To discriminate between spots inside and outside the
cell nucleus, DAPI staining was used for the nuclear segmentation. With our
program more than 500 confocal images were successfully analyzed.
The characterization of tumors is highly relevant for tumor diagnostics and treatment
planning. Due to the appearances of APBs in healthy tissue, one important question
remains. How tightly are these structures linked to the ALT-mechanism? Further investi-
gation is needed to clarify if in healthy tissue APBs are induced by the ALT mechanism or
other nuclear processes besides ALT. Therefore, the characterization and understanding
of telomere maintenance mechanism in tumorigenesis could have important implications
in the development new treatments for these malignancies.
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1 General Introduction
1.1 Cancer: General aspects
Cancer is one of the most common causes of death in Germany and the Western world
after cardio-vascular diseases. In Germany, in 2006, approximately 22% and 28% of all
deaths of women and men, respectively, were cancer-related. More recently, Jemal et al.
(2008, 2005) estimated that cancer will be the most frequent cause of death in the near
future.
In 2000, Hanahan and Weinberg (2000) summarized six universal hallmarks of cancer
(Table 1.1), which are crucial steps in the transformation process from normal to malig-
nant cells. In each malignant transformation not all six hallmarks have to be fulﬁlled and
the mechanistic pathway may vary from cell to cell. Nevertheless, most tumor cells have
acquired more or less of these properties. These capabilities described in malignant cells
are gained during transformation and induced by genomic and/or epigenetic mutation.
This does not mean that every hallmark needs to be caused by an individual mutation.
Mutator genes with several control functions can lead to gains of several functions at
once. These changes can be point mutation, microsatellite instability or loss of heterozy-
gosity, and aﬀect genes that control DNA replication, cell cycle checkpoints and DNA
repair (Klein et al. 2007). In general, cancer cells acquire their functional capabilities
by mutations that aﬀect two classes of genes: oncogenes and tumor suppressor genes.
Cancer-promoting oncogenes are activated by gain-of-function and are mostly involved
in pathways that change the properties of the transformed cells including proliferation,
Table 1.1: The six hallmarks of cancer (Hanahan and Weinberg 2000)
Hallmarks of cancer Cellular eﬀects
Evasion of apoptosis Allows cell growth despite of genetic mutations
and internatal or external anti-growth signal(s)
Self-suﬃcient in growth signals Unchecked growth
Insensitivity to anti-growth signals Unchecked growth
Sustained angiogenesis Allows tumor to growth beyond limitations
of passive nutrition
Limitless replicative potential Immortality of cancer cells
Tissue invasion Metastasis
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1 General Introduction
apoptosis prevention, loss of tissue boundaries and invasion. A predominant example
for a proto-oncogene is RAS, which is important for the molecular switch between apop-
tosis and survival of normal cells. RAS mutation promotes survival of tumor cells and
is constitutively active and therefore insensitive to cellular negative control mechanisms
(Klein et al. 2007).
Tumor suppressor genes, on the other hand, are inactivated in tumors by loss-of-
function mutation and normally protect cells from cancer. The normal function of
tumor suppressor genes are regulation of DNA replication, DNA repair, cell cycle control,
cellular orientation within a tissue, adhesion within tissues or promotion of apoptosis.
The most famous example of a tumor suppressor gene is TP53, which is aﬀected in
almost all cancers (Wang and Harris 1996; Weinberg 2007). Nevertheless, the formation
of a tumor remains a complex process that usually proceeds over decades.
Nonetheless, nearly every tissue of an organism can be aﬀected by cancer. Frequently
aﬀected tissues in both genders are gut, lung, stomach and bladder. For women, the
tissue mostly eﬀected by cancer is breast tissue and for men prostate tissue. The majority
of human tumors arise from epithelial tissues, whereas a small group is derived from non-
epithelial tissues sharing a common origin in the mesoderm of the embryo. The latter,
the sarcomas, are focus of this study.
1.2 Soft tissue sarcomas: An overview
Sarcomas are a heterogeneous group of rare tumors that arise predominantly from the
embryonic mesoderm and share a putative mesenchymal cell origin (Table 1.2). The dif-
ferent types of sarcomas include bone sarcomas, Ewing`s sarcomas, peripheral primitive
neuroectodermal tumors and soft tissue sarcomas, the latter being the most frequent.
Soft tissue sarcomas can involve connective tissue structures as well as viscera and in-
tegument. There are approximately 9 000 new cases diagnosed as soft tissue sarcomas
per year in the United States, which constitutes less than 1% of adult solid malignancy.
There are nearly 3 660 deaths by soft tissue sarcomas per year (Jemal et al. 2004).
Soft tissue sarcomas may occur anywhere in the body, but they are often located at the
extremities (59%), the trunk (19%), the retroperitoneum (15%), or the head and neck
(9%) (DeVita et al. 2001). Currently, the soft tissue sarcoma classiﬁcation includes more
than 50 diﬀerent histologic subtypes. The most frequent types are malignant ﬁbrous
histiocytomas (28%), leiomyosarcomas (12%), liposarcomas (15%), synovial sarcomas
(10%), and malignant peripheral nerve sheath tumors (6%) (Coindre et al. 2001) (see
also section 1.3). The most common soft tissue sarcomas of childhood are the rhab-
domyosarcomas.
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1.2 Soft tissue sarcomas: An overview
Table 1.2: Typiﬁcation of soft tissue sarcomas (Fletcher et al. 2002)
Histologic subtypes Tumor (e.g.)
SOFT TISSUE TUMORS
Fibroblastic/Myoﬁbroblastic tumors Fibrosarcoma
Fibrous histiocytoma
Adipocytic tumors Liposarcomas
Lipomatosis
Smooth muscle tumors Leiomyosarcoma
Angioleiomyoma
Skeletal muscle tumors Rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Vascular tumors Angiosarcoma of soft tissue
Epithelioid haemangioendothelioma
Pericytic tumors Myopericytoma
Glomus tumors
So-called ﬁbrohistiocytic tumors Giant cell tumors of tendon sheath
Deep benign ﬁbrous histiocytoma
Chondro-osseous tumors Soft tissue chondroma
Extraskeletal osteosarcoma
Tumors of uncertain diﬀerentiation Synovial sarcomas
Clear cell sarcomas of soft tissue
BONE TUMORS
Cartilage tumors Osteochondroma
Osteogenic tumors Osteoid osteoma
Fibrogenic tumors Desmoplastic ﬁbroma of bone
Fiborhistiocytic tumors Malignant ﬁbrous histiocytoma of bone
Ewing sarcomas/ Primitive neuroectodermal tumors Ewing tumor/ PNET
Haematopoietic tumors Plasma cell myeloma
Giant cell tumors Giant cell tumors
Notochordal tumors Chordoma
Vascular tumors Angiosarcoma
Myogenic, lipogenic, neural, and epithelial tumors Schwannoma
Tumors of undeﬁned neoplastic nature Simple bone cyst
Congenital and inherited syndromes Werner syndrome
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1.2.1 Epidemiology and genetics
Soft tissue sarcomas have no clearly deﬁned etiology even though several associated
or predisposing factors have been identiﬁed. In general, soft tissue sarcomas occur
de novo and do not seem to result from malignant changes or the dediﬀerentiation of
benign tumors. Despite the high variety of histological subtypes, soft tissue sarcomas
have many clinical and pathologic features in common. For instance, most soft tissue
sarcomas show a similar clinical behavior as deﬁned by the staging system, which is
determined by the anatomic location (depth), grade, and size of the tumor. Soft tissue
sarcomas disseminate predominantly hematogenous. Lymph node metastasis are less
than 5% except for a few histologic subtypes of soft tissue sarcomas, such as synovial
sarcomas and rhabdomyosarcomas (Fong et al. 1993).
The development of soft tissue sarcomas as a result of radiation therapy are shown
in several studies. The risk for a soft tissue sarcoma is increased eightfold to 50-fold in
patients treated with radiation therapy of breast, cervix, ovary or lymphatic system can-
cers. The most common histologic subtypes of radiation-induced tumors are extraskeletal
osteogenetic, malignant ﬁbrous histiocytomas and angiosarcomas/lymphangiosarcomas
(Brady et al. 1992; Zahm and Fraumeni 1997). Another known risk factor for the devel-
opment of lymphangiosarcomas is lymphedema (Muller et al. 1987). Further risk factors
include exposure to certain chemicals like phenoxyherbicides and chlorphenols (Hardell
and Sandström 1979; Smith et al. 1984).
Similar to other cancers, genetic factors play a decisive role in the initiation and
progress of sarcomas. It is supposed that genetic mutations in pluripotent mesenchy-
mal stem cells give rise to malignant transformation. Furthermore, speciﬁc inherited
genetic alteration are associated with an increasing risk of the bone and soft tissue sarco-
mas. These include, for example, neuroﬁbromatosis typ1 (von Recklinghausen disease),
retinoblastoma, Li-Fraumeni syndrome, Gardner syndrome and Werner syndrome.
The onco-genes that have been implicated in malignant formation and progression
are MDM2, MYCN, ERBB2 and members of the RAS -family. In several subtypes
of soft tissue sarcomas, ampliﬁcation of these genes correlates with an adverse patient
outcome (Levine 1999). Cytogenetic analysis of these tumors identiﬁed chromosomal
translocations that code for onco-proteins associated with speciﬁc histological subtypes.
Well characterized gene rearrangements are found, for example, in Ewing`s sarcomas
(EWS-FLI-1 fusion), myxoid liposarcomas (TLS-CHOP fusion) and synovial sarcomas
(SSX-SYT fusion) (Vorburger and Hunt 2002). Further typical gene rearrangements that
are found in sarcomas are listed in Table 1.3.
Tumor suppressor genes play an important role in cell growth inhibition and in the
suppression of growth. These genes can be inactivated by two events: hereditary or
sporadic. Two such genes that are relevant in soft tissue tumors are the retinoblastoma
gene RB1 and the tumor suppressor gene TP53. Deletions or mutations in the RB1
gene can induce the development of retinoblastomas, soft tissue sarcomas and sarcomas
of the bone. Mutation in the tumor suppressor gene TP53 is the most frequent mutation
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Table 1.3: Speciﬁc translocation in soft tissue sarcomas (Helman and Meltzer 2003)
Tumor type Chromosomal
translocation
Involved genes
Ewing-Sarkom/PNET t (11;22) (q24; q12) EWSR1-FLI1
t (21;22) (q22; q12) EWSR1-ERG
t (7;22) (p22; q12) EWSR1-ETV1
Desmoplastic small round-cell tumor t (11;22) (p13; q12) EWSR1-WT1
Clear cell sarcomas of soft tissue t (11;22) (q13; q12) EWS-ATF1
Myxoides chondrosarcoma t (9;22) (q31; q12) EWS-TEC
Alveolar rhabdomyosaroma t (2;13) (q35; q14) PAX3-FOXO1A
t (1;13) (p36; q14) PAX7-FOXO1A
Myxoid liposarcomas t (12;16) (q13; p11) FUS-DDIT3
t (12;22) (q13; q12) EWSR1-DDIT3
Synovial sarcomas t (X;18) (p11; q11) SYT-SSX
Dermatoﬁbrosarcoma protuberans t (17;22) (q22; q13) COL1A1-PDGFB
in human solid tumors and is also noted in 30% to 40% of soft tissue tumors. Some rare
cases of soft tissue sarcomas (i.e. with Li-Fraumenti syndrome) arise due to germline
mutations in the gene TP53 (Latres et al. 1994; Hieken and Das Gupta 1996).
1.2.2 Grading and staging of soft tissue sarcomas
Developing robust und reproducible criteria for grading and staging systems is critical
in patient management. Staging and grading enable the physician to plan therapies, the
comparison of experiences among centers and diﬀerent treatments over time.
The grading system, based on the histological parameters predicts the malignancy of
these tumors. The criteria deﬁning the grade are the degree of diﬀerentiation, necrosis
as well as the number of mitoses. A score is attributed to each of the three parameters
independently. The grade is obtained by adding the three attributed scores (Table 1.4).
Staging is based on clinical and histological parameters and provides information
concerning the extent of the tumor, with more information concerning prognosis and
therapies.
For staging, the classiﬁcation of soft tissue sarcomas by the TNM-system is needed
and incorporates tumor size and depth (T), regional lymph node involvement (N) and
distant metastasis (M) (Table 1.5). The TNM-classiﬁcation comprises a 2, 3 and 4-
tiered grading system (Table 1.6) (Fletcher et al. 2002).
The staging system was developed by the international Union against Cancer (UICC)
and the American Joint Committee on Cancer (AJCC). It is clinically useful and acts
is associated with diﬀerent prognosis.
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Table 1.4: Histopathologic grading of soft tissue sarcomas. Modiﬁed from Coindre et al. (1986)
Score Description
Tumor diﬀerentiation
Score 1 sarcomas closely resembling normal adult mesenchymal tissue
Score 2 sarcomas for which histological typing is certain
Score 3 embryonal and undiﬀerentiated sarcomas, sarcomas of doubtful type
Mitotic count
Score 1 0 - 9 mitoses per 10 high power ﬁeld*
Score 2 10 - 19 mitoses per 10 high power ﬁeld*
Score 3 20 or more mitoses per high power ﬁeld*
Tumor necrosis
Score 0 no necrosis
Score 1 less than 50% tumor necrosis
Score 2 50% or more tumor necrosis
Histological grade
Grade 1 Score 2-3
Grade 2 Score 4-5
Grade 3 Score 6-8
*One ﬁeld measures 0,1734 mm2
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Table 1.5: TNM-classiﬁcation of soft tissue sarcomas. Modiﬁed from Fletcher et al. (2002)
Stage description local extent
T Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor maximal 5 cm in greatest dimension
a) Superﬁcial tumor
b) Deep tumor
T2 Tumor bigger than 5 cm in greatest dimension
a) Superﬁcial tumor
b) Deep tumor
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
G Histologic grade (G)
GX Grade cannot be assessed
G1 Well-diﬀerentiated
G2 moderately diﬀerentiated
G3 - 4 poorly diﬀerentiated / undiﬀerentiated
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Table 1.6: Translation table for three and four to two grade system. Modiﬁed from Fletcher et al. (2002)
TNM two
grade system
Three grade system Four grade system
Low grade Grade 1 Grade 1
Grade 2
High grade Grade 2 Grade 3
Grade 3 Grade 4
The staging system described by UICC 2002 including four major stages is listed in
Table 1.7 and is deﬁned as follows:
 Stage IA: low grade, small, superﬁcial or deep, no sign of any spread
 Stage IB: low grade, large, superﬁcial or deep, no sign of any spread
 Stage IIA: high grade, small, superﬁcial or deep, no sign of any spread
 Stage IIB: high grade, large, superﬁcial, no sign of any spread
 Stage III: high grade, large, deep, no sign of any spread
 Stage IV: any grade, any T, regional lymph node metastasis, no distant metastasis
or any grade, any T, any N, distant metastasis
Authentic predictive factors are essential for the classiﬁcation of patients with cancer
into useful staging categories. Due to the new insights into the molecular biology of
cancer, new speciﬁc markers (e.g. c-Kit in gastrointestinal stromal tumors or estrogen
receptor in breast cancer; Lahat et al. (2009)) for characterization have been found.
The development of new techniques such as tissue microarray analyzes, have resulted
in powerful tools for analyzing a large number of tumor entities to detect expression
levels of relevant genes and their related proteins. Evaluation of hundreds of molecular
markers in the same tumor specimens can be integrated in describing tumor progression,
treatment response and survival.
1.2.3 Therapy
When the histological diagnosis and grade is established, a multidisciplinary team of
surgeons, radiologist and medical oncologists should plan the most eﬀective therapy for
the patient.
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Table 1.7: Staging of soft tissue sarcomas (Fletcher et al. 2002)
Stage IA T1a N0, NX M0 low grade
T1b N0, NX M0 low grade
Stage IB T2a N0, NX M0 low grade
T2b N0, NX M0 low grade
Stage IIA T1a N0, NX M0 high grade
T1b N0, NX M0 high grade
Stage IIB T2a N0, NX M0 high grade
Stage III T2b N0, NX M0 high grade
Stage IV any T N1 M0 any G
any T Jedes N M1 any G
1.2.3.1 Surgery
Surgery remains the primary treatment of sarcomas. Nevertheless the physician must
balance the goal of minimizing local and distant recurrence with the aim of maintaining
function and quality of life. In general, the extent of the excision is based upon the size of
the tumor, its anatomic location relating to normal structures and the degree of function
that would be lost after surgery. For subcutaneous or intramuscular high grade sarcomas
less than 5 cm or low grade tumors of any size, surgery alone should be suﬃcient if wide
resection margins can be achieved. In case of extramuscular involvement or if the tumor
is too close to the resection margins, adjuvant radiotherapy can be added to reduce local
recurrence (Fletcher et al. 2002).
1.2.3.2 Adjuvant and neo-adjuvant therapy
For high grade sarcomas, there are certain treatment strategies with the aim of achieving
good local control and also reducing the risk of development of subsequent metastasis.
The outcome of systemic chemotherapy depends on the entity of the sarcomas. For
certain soft tissue tumors, adjuvant chemotherapy is reasonable even if the primary
tumor is resected, because of the risk of developing subsequent metastasis. In general,
the histological type and location of soft tissue sarcomas are important predictors of
sensitivity to chemotherapy. The most frequently used drugs in soft tissue sarcomas are
doxorubicin and ifosfamide (Fletcher et al. 2002).
For the treatment of large high grade extremity sarcomas several multimodal protocols
of chemotherapy, radiation and surgery have been investigated. In general there are three
approaches (Fletcher et al. 2002):
1. neoadjuvant chemotherapy > surgery > adjuvant chemotherapy + post operative
radiotherapy
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2. neoadjuvant chemotherapy interdigitated with preoperative radiotherapy > surgery
> adjuvant chemotherapy
3. neoadjucant chemotherapy > preoperative radiotherapy > surgery > adjuvant
chemotherapy
Because of the large size, the tendency to invade nearby organs and the diﬃculty
in achieving a complete surgical resection of retroperitoneal and visceral sarcomas, a
complex strategy is demanded. For this, a new modality has been designed termed in-
traoperative radiotherapy (IORT). This approach allows the sterilization of microscopic
diseases in situ with high single doses of radiation while minimizing the dose to adjacent
normal tissues. For these reasons, patients with recurrent and locally advanced malig-
nancies, IORT is appropriate, in addition to resection (Tran et al. 2008). Nevertheless,
local control remains a signiﬁcant problem that leads to unresectable local disease and
death in many cases.
1.3 Analyzed soft tissue sarcomas
1.3.1 Liposarcomas
Adipose tumors incorporate the most common group of mesenchymal tumors, because of
the high prevalence of benign lipomas and benign angiolipomas. Liposarcomas represent
the largest group of soft tissue sarcomas with three main subtypes:
 well diﬀerentiated/dediﬀerentiated
 myxoid
 pleomorphic
Histological subtypes of liposarcomas are diﬀerent entities with diﬀerent morphology,
genetics and natural histology. The distinctive karyotypic aberrations can assist in
diagnosis (Fletcher et al. 2002).
1.3.1.1 Dediﬀerentiated Liposarcomas
Dediﬀerentiation, the loss of form or function, occurs in approximately 10% of well
diﬀerentiated liposarcomas of any subtype. The risk of dediﬀerentiation seems to be
higher in deep located lesions and is signiﬁcantly less in the limbs. The probability of
dediﬀerentiation represents more a time dependent than a site-dependent phenomenon.
There is no sex predilection. Dediﬀerentiated liposarcomas arise most frequently de novo
while 10% occur as recurrence (Weiss 2001).
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The retroperitoneum is the most frequent location of dediﬀerentiated liposarcomas,
followed by the soft tissue sarcomas of the extremities (ratio of 3:1). Rare sites of
locations include the spermatic cord, the head and neck and subcutaneous tissue.
Dediﬀerentiated liposarcomas most often have ring or giant marker chromosomes even
if the number of karyotyped cases is too little to establish signiﬁcant diﬀerences to well
diﬀerentiated liposarcomas (Fletcher et al. 1996; Meis-Kindblom et al. 2001; Mertens et al.
1998). Molecular cytogenetics and genetic studies with comparative genomic hybridiza-
tion (CGH) and ﬂuorescence in situ hybridization (FISH) have identiﬁed an ampliﬁca-
tion of the 12q13-21 region associated with co-ampliﬁcation of other regions. Southern
blot analyzes revealed MDM2 ampliﬁcation in 5/5 retroperitoneal cases, but no ampli-
ﬁcation in 4/4 non-retroperitoneal dediﬀerentiated liposarcomas cases. In addition the
non-retroperitoneal cases without ampliﬁcation on the MDM2 locus are found to have
TP53 mutations (Pilotti et al. 1997; Schneider-Stock et al. 1998; Dei Tos et al. 1997) .
Dediﬀerentiated liposarcoma is characterized by relapse in at least 40% of cases. The
incidence of distant metastases ranges from 15-20% with an overall mortality between
28 and 30% at ﬁve years follow-up (Henricks et al. 1997; McCormick et al. 1994; Weiss
and Rao 1992). The anatomic location of dediﬀerentiated liposarcomas is the most
important prognostic factor and retroperitoneal lesions have the worst outcome. The
size of dediﬀerentiated regions does not seem to inﬂuence the clinical outcome. Even
with high grade morphology, dediﬀerentiated liposarcomas are less aggressive in their
clinical behavior than other types of high grade tumors such as pleomorphic sarcomas.
The cause of this diﬀerence is not yet known, but it is to be assumed that the absence
of complex karyotypic aberrations as well as integrity of the TP53 gene in most cases
may explain the discrepancy between morphology and clinical outcome (McCormick et al.
1994; Weiss and Rao 1992; Cordon-Cardo et al. 1994).
1.3.1.2 Myxoid Liposarcomas
Myxoid liposarcomas (MLS) represent approximately 10% of all adult soft tissue sar-
comas and they account for more than one third of liposarcomas. The most common
location of myxoid liposarcomas is the deep soft tissue of the extremities and, in more
than two-thirds of the cases, MLS occurs within the musculature of the thigh. MLS
arise less frequent in the retroperitoneum or in subcutaneous tissue.
In more than 90% of cases the karyotypic hallmark of myxoid and round cell liposar-
comas is the t(12;16)(q13;p11) translocation, wich leads to the fusion of the DDIT3
(a.k.a.CHOP) and FUS (a.k.a. TLS ) genes and generates the hybrid protein FUS/DDIT3
(Table 1.3). A rare variant chromosomal translocation in MLS is t(12;22)(q13;q12). In
these cases, DDIT3 fuses with EWS (Sreekantaiah et al. 1992; Turc-Carel et al. 1986).
The occurrence of the FUS/DDIT3 fusion in MLS entity is highly sensitive and speciﬁc
and is absent in other cases, which show features of MLS (Antonescu et al. 2000a). High
histologic grade and TP53 overexpression are predictors of unfavorable outcome. In
comparison with some other translocation-associated sarcomas, the presence of fusion
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transcripts in MLS does not seem to inﬂuence the impact on histologic grade or clinical
outcome (Antonescu et al. 2001; Smith et al. 1996).
1.3.1.3 Pleomorphic Liposarcomas
The rarest subtype of liposarcomas are pleomorphic liposarcomas, accounting for about
5% of all liposarcomas and 20% of pleomorphic sarcomas. The majority of this tumor
entity arises in older patients (>50 years). There is no sex predilection (Azumi et al.
1987; Fletcher 1992).
The occurrence of pleomorphic liposarcomas is most common in the extremities whereas
the trunk and the retroperitoneum are infrequently aﬀected. Although most cases arise
in deep soft tissue, rare sites of involvement include regions such as the mediastinum,
the paratesticular region and dermis (Klimstra et al. 1995; Cai et al. 2001; Dei Tos et al.
1998; Downes et al. 2001).
The karyotypic data from 11 investigated pleomorphic liposarcomas have shown a
high number of chromosomal imbalances, complex structural rearrangements, includ-
ing numerous indeﬁnable marker chromosomes and polyploidy (Sreekantaiah et al. 1992;
Mertens et al. 1998). The intratumoral heterogeneity has made the identiﬁcation of
speciﬁc rearrangements challenging.
Unlike well diﬀerentiated liposarcomas, ampliﬁcation of the 12q14-15 region did not
appear consistently in all pleomorphic liposarcomas (Fritz et al. 2002). Analyzes by
comparative genomic hybridization (CGH) identiﬁed a number of chromosomal gains
and losses (Szymanska et al. 1996). The ampliﬁcation of the MDM2 gene was detected
in about one third of the cases and could be associated with the occurrence of ring
chromosomes. In 4/9 of cases studied, TP53 alterations or loss of heterozygosity were
observed, whereas all 4 cases were negative for MDM2 ampliﬁcation (Schneider-Stock
et al. 1998; Nilbert et al. 1994).
For pleomorphic liposarcomas, tumor depth and size, the amount of mitoses and necro-
sis are associated with clinical prognosis (Downes et al. 2001; Miettinen and Enzinger
1999).
1.3.2 Leiomyosarcomas
Leiomyosarcoma of the soft-tissue usually occurs in middle-aged or older persons even
though it may develop in young adults and in children (de Saint Aubain Somerhausen
and Fletcher 1999; Swanson et al. 1991). Leiomyosarcoma arise most frequently in the
retroperitoneum and are the predominant sarcomas arising from larger blood vessels.
In general, tumor location is associated with sex incidence. A clear majority of pa-
tients with retroperitoneal and inferior vena cava leiomyosarcoma are women, but there
is no sex predilection of leiomyosarcoma in other soft tissue sites (Hisaoka et al. 2008;
Berlin et al. 1984; Kevorkian and Cento 1973). The most common location of soft tis-
sue leiomyosarcoma is the retroperitoneum followed by leiomyosarcoma arising in large
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blood vessels such as the inferior vena cava or the large veins of the lower extremity,
and sometimes in arteries. A third group constitutes leiomyosarcomas involving non-
retroperitoneal soft tissue. This subtype is found for example in the lower extremity,
intramuscular or subcutaneous regions (Dahl and Angervall 1974; Farshid et al. 2002;
Hashimoto et al. 1986).
Karyotypes from around 100 leiomyosarcomas have shown complex rearrangements
and no consistent aberrations (Wang et al. 2001). Chromosomal losses include the regions
3p21-23, 8p21-pter, 13q12-13 and 13q32-qter, whereas the chromosomal regions 1q21-
31 show gains. In addition, comparative genomic hybridization (CGH) has identiﬁed
numerical changes, including gains of chromosomes 1, 15, 17, 19, 20, 22 and losses
of chromosomes 1q, 2, 4q, 9p, 10, 11q, 13q and 16. No signiﬁcant diﬀerences among
the diﬀerent subtypes are found, but tumor size-related diﬀerences are observed, such
as gains of 16p and 17p for smaller tumors and gain of 6p and 8q for larger tumors
(Mandahl et al. 2000; Wang et al. 2001; El-Rifai et al. 1998). Further molecular genetic
analyzes show abnormalities of the RB1 gene as well as proteins involved in the Rb-
cyclinD pathway (Stratton et al. 1990). Involvement of the two genes TP53 and MDM2
appears less frequently than in other sarcomas types (Dei Tos et al. 1996).
Soft tissue leiomyosarcomas are marked by local recurrence and distant metastasis
whereas local lymph node metastasis is rare. The most important prognostic factors
are localization and size of the tumor. The majority of cases of leiomyosarcomas of the
retroperitoneum are lethal due to the large size and the diﬃculty or impossibility in re-
secting the tumor completely. Even when leiomyosarcomas are completely resected, there
is still a poor prognosis due to local recurrence and metastasis of soft tissue leiomyosar-
coma, which become obvious within the ﬁst few years and, in some cases, up to 10 years
after diagnosis (Fletcher et al. 2002).
1.3.3 Synovial Sarcomas
Synovial sarcomas accounts for 5 to 10% of soft tissue sarcomas (Kransdorf 1995). They
arise mainly in young adults and more common in males even though rare cases are
reported in the elderly (Fletcher et al. 2002). Despite of its nomenclature, synovial
sarcomas is unrelated to synovia and less than 5% originate within a joint or bursa,
whereas more than 80% arise in deep soft tissue of extremities. About 5% occur in
the head and neck region, however it seems that any site can be aﬀected (Argani et al.
2000; Fisher 1998; Flieder and Moran 1998). There are no speciﬁc predisposing factors,
but synovial sarcomas has a chromosomal translocation that is probably relevant in
pathogenesis.
The cytogenetic hallmark of synovial sarcomas is the t(X;18)(p11;q11) translocation,
found in about 90% of the 150 cases investigated (Mitelman and Mertens 2009). The
genes aﬀected by the t(X;18) translocation are isolated and include the SS18 (=synovial
sarcoma translocation, chromosome 18 ) on chromosome 18 and the genes SSX1, SSX2
and SSX4 on chromosome X (Clark et al. 1994; de Leeuw et al. 1995). Several stud-
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ies have shown that the t(X;18) translocation arises exclusively in synovial sarcomas
whereas two-thirds show an SS18/SSX1 fusion, one-third an SS18/SSX2 fusion and
three separate cases an SS18/SSX4 fusion of at least 350 investigated synovial sarcomas
(Sandberg and Bridge 2002; dos Santos et al. 1997, 2001).
The probability of recurrence of synovial sarcomas is approximately 50%, usually
within 2 years but sometimes up to 30 years after diagnosis (Weiss 2001). About 40%
of the tumors show metastasis, commonly to lung, and bone and in some cases, with
regional lymph node involvement. Postoperative radiotherapy and local excision can
control local recurrence. The following features are predictors for a good patient outcome
in synovial sarcomas (Lewis et al. 2000; Friedberg et al. 1999; Spillane et al. 2000):
 occurrence in childhood patient
 tumors less than 5 cm in diameter
 tumors with less than 10 mitosis /hpf (Table 1.4)
 tumors with no necrosis (Table 1.4)
 tumor is eradicated locally
Synovial sarcomas with the SS18/SSX2 translocation have a better prognosis (An-
tonescu et al. 2000b; Nilsson et al. 1999). The overall 5 year survival rate is between
36-76% and the 10 year survival rate is between 20-63% (Weiss 2001).
1.3.4 Maligne Peripheral Nerve Sheath Tumors (MPNST)
MPNST account for nearly 5% of malignant tumors of soft tissue (Lewis and Brennan
1996). Almost one half to two thirds arise from neuroﬁbromatosis (Ducatman et al.
1986), often of the plexiform type and in association with neuroﬁbromatosis type 1
(NF1). Less frequently, MPNST arise de novo from peripheral nerves (Scheithauer and
Woodruﬀ J.M. 1999). Only a few cases occur in conventional schwannomas (Woodruﬀ
et al. 1994), ganglioneuroblastomas/ ganglioneuromas (Ricci et al. 1984) or phaeochro-
mocytomas (Sakaguchi et al. 1996).
Adults in the third to the sixth decades of life are most frequently aﬀected by MP-
NST. Patients with NF1-associated MPNST are approximately 28-36 years old, whereas
patients with sporadic MPNST are about 40-44 years (Ducatman et al. 1986). NF1-
associated MPNST are more frequent in males, while non-NF1-associated cases are more
frequent in females. Large and medium-size nerves are more often involved than small
nerves. Most frequently aﬀected sites include the buttock and thigh, brachial plexus
and upper arm and the paraspinal region, where the sciatic nerve is most commonly
involved (Best 1987). MPNST occur less frequently, for example intraparachymal or in
the cranial nerve (Sharma et al. 1998).
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Genetic analyses in sporadic and NF1-associated MPNST have shown complex kary-
otypic abnormalities that are both numerical and structural. These ﬁndings include
near-triploid or hypodiploid chromosome numbers, chromosomal losses, loss of genetic
material related to structural aberrations and recombinations (Sharma et al. 1998). Anal-
yses of 10 MPNST have shown that structural abnormalities of chromosome 17 involving
the NF1 and the TP53 loci were frequent. Gains of chromosomes 2 and 14 and losses of
chromosomes 13, 17 and 18 are noted, but no cytogenetic diﬀerences between sporadic
and NF1-associated cases are established (Jhanwar et al. 1994; Kobayashi et al. 2006).
In NF1-associated MPNST cases, inactivation of both NF1 alleles are detected, in-
volving this gene in MPNST development (Legius et al. 1993). Sporadic MPNST also
show alterations at the NF1 locus, which are thought to be involved in early stages
of nerve sheath tumorigenesis such as in neuroﬁbroma-genesis rather than in malignant
progression to MPNST. The latter one seems to be associated with alterations of genes
controlling cell cycle regulation such as the gene TP53, which is mutated and altered in
MPNST (Legius et al. 1994). In addition, homozygous deletion of the gene CDKN2A,
which encodes the p16INK4a and p14ARF cell cycle inhibitory molecules, is found in the
progression of neuroﬁbromatosis to MPNST but not in neuro-ﬁbromas. This deletion
also inactivates the adjacent CDKN2B gene that encodes the p15 molecule (Perrone
et al. 2003; Nielsen et al. 1999). Furthermore, these events seem to inactivate the p53
and pRb regulatory pathways in almost 75% of MPNST cases (Perrone et al. 2003).
MPNST are extremely aggressive tumors with a poor prognosis, except for those with
perineural cell diﬀerentiation. The mortality is about 60% Ducatman et al. (1986), and
even higher in patients with paraspinal lesions (80%) (Kourea et al. 1998) and those
with divergent angiosarcomas (100%) (Scheithauer and Woodruﬀ J.M. 1999). The 5-
and 10-years survival rates are between 34% and 23% (Ducatman et al. 1986).
1.3.5 Malignant Fibrous Histiocytoma (MFH)
Although the precise origin of MFH has been discussed for decades, the term of MFH
gives the impression that the origin of the tumor cells is ﬁbroblastic and histiocytic.
With the improvement of diagnostic techniques such as immunohistochemistry, cell cul-
ture and electron microscopy, a number of studies have tried to clarify the histogenesis
of MFH. These studies suggest that MFH is a sarcomas of either ﬁbroblast or primi-
tive mesenchymal origin. While the nomenclature of MFH is still discussed, the WHO
maintained the term MFH in its 2002 classiﬁcation of soft tissue tumors. Currently ﬁve
subtypes of MFH are distinguished which are listed in Table 1.8, including the old and
the current nomenclature (Al-Agha and Igbokwe 2008).
1.3.5.1 Undiﬀerentiated High-grade Pleomorphic Sarcomas (WHO 2002)
Undiﬀerentiated high-grade pleomorphic sarcomas arise most frequently in the extrem-
ities, especially the lower limb, and less commonly in the trunk. The second most
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Table 1.8: Old and current nomenclature of MFHs (Al-Agha and Igbokwe 2008)
old
Nomenclature
current Nomenclature of
MFH (WHO 2002)
Tumor-Category
storiform-pleomorphic MFH undiﬀerentiated high-grade pleomorphic sarcomas Fibrohistiocytic
Myxoid MFH Myxoﬁbrosarcoma Myoﬁbroblastic
Giant cell MFH undiﬀerentiated pleomorphic sarcomas Fibrohistiocytic
with giant cells
Inﬂammatory MFH undiﬀerentiated pleomorphic sarcomas Fibrohistiocytic
with prominent inﬂammation
Angiomatoid MFH Angiomatoid ﬁbrous histiocytoma Tumors of
uncertain diﬀerentiation
common cases occur in deep (subfascial) tissue, whereas less than 10% are primarily
subcutaneous. Undiﬀerentiated high-grade pleomorphic sarcomas are aggressive tumors
with an 5-year survival rate of 50-60% (about genetics see chapter 1.3.5.4) (Fletcher et al.
2002).
1.3.5.2 Undiﬀerentiated Pleomorphic Sarcomas with Giant Cells (WHO 2002)
Tumors in this general category arise predominantly in deep soft tissue of the limbs or
trunk. The most common organs in which giant cell-rich tumors occur include pancreas,
thyroid, breast and kidney. In consideration of prognostic factors, undiﬀerentiated high-
grade sarcomas with osteoclastic giant cells have a similar prognosis to other pleomorphic
sarcomas (about genetics see section 1.3.5.4) (Fletcher et al. 2002).
1.3.5.3 Undiﬀerentiated Pleomorphic Sarcomas with Prominent Inﬂammation
The most frequent location of undiﬀerentiated pleomorphic sarcomas with prominent
inﬂammation is the retroperitoneum, but intra-abdominal and deep soft tissue location
have also been observed. Two-third of the patients with persistence or recurrence died
due to their diseases, whereas one-fourth of patients developed distant metastasis. Sim-
ilar to other retroperitoneal sarcomas, these patients have a poor prognosis which is
related to the extent of the tumor and the diﬃculty of complete resection at the time of
diagnosis (about genetics see section 1.3.5.4) (Fletcher et al. 2002).
1.3.5.4 Genetics in MFH
On the basis of the shifting diagnostic criteria between the past and the present, the
genetic aspects of malignant ﬁbrous histiocytomas are challenging to evaluate. In con-
sideration of these shortcomings, cytogenetic aberration are observed in more than 50
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cases of MFH subtypes such as storiform or pleomorphic (Mitelman and Mertens 2009).
Currently just a few cases of giant cell and inﬂammatory MFH are investigated. How-
ever, genetic analyses have shown complex karyotypes with extensive intratumoral het-
erogeneity and chromosome numbers in the triploid or tetraploid range (Mandahl et al.
1985; Molenaar et al. 1989; Orndal et al. 1994; Simons et al. 2000). Although no spe-
ciﬁc structural or numerical aberrations are observed, telomeric associations and ring
chromosomes are frequent. Due to the occurrence of numerous marker chromosomes in
almost all cases, the proper determination of genomic imbalances is diﬃcult to assess
from these cytogenetic data (Fletcher et al. 2002).
Genomic imbalances include frequent losses of the chromosomal region 2p24-pter and
2q32-qter, and losses on 11, 13 and 16 (Larramendy et al. 1997; Mairal et al. 1999; Parente
et al. 1999; Simons et al. 2000) whereas gains are found on 7p15-pter, 7q32 and 1p31.
Several proto-oncogenes such as SAS, MDM2, CDK4 or CHOP are related to the
chromosome region 12q13-15 and are suggested to be involved in the development of
MFH-like pleomorphic sarcomas. The candidate gene MASL1 is found on the chromo-
somal region 8p23.1 (Berner et al. 1997; Reid et al. 1996; Sakabe et al. 1999).
No clear relationships are found between clinical outcome and alterations (such as
mutation and/or deletion) of TP53, RB1 and CDKN2 although they are suggested to
play a crucial role in pleomorphic sarcomas development (Reid et al. 1996; Simons et al.
2000).
1.3.5.5 Myxoﬁbrosarcoma
Myxoﬁbrosarcoma is one of the most frequent sarcomas that commonly occurs in older
patients with a slight male predilection. The most common aﬀected sites are the limbs
including the limb girdles. These tumors occur less frequently in the trunk, in the
head and neck, and on the hands and feet. They are seen only rarely in the retroperi-
toneum and abdominal cavity. Interestingly, about two-third of myxoﬁbrosarcoma arise
in dermal/subcutaneous tissue with a proportion occurring in the underlaying fascial
and skeletal muscle (Mentzel et al. 1996; Merck et al. 1983; Weiss and Enzinger 1977).
In about 25 cases diagnosed as myxoid MFH or myxoﬁbrosarcoma cytogenetic aberra-
tions such as complex karyotypes with high intratumoral heterogeneity and triploid or
tetraploid chromosomes are detected. Ring chromosomes were found in ﬁve investigated
cases. In addition, comparative genomic hybridization (CGH) was identiﬁed genomic
imbalances, including loss of 6p and gains of 9q and 12q (Mandahl et al. 1985; Molenaar
et al. 1989; Orndal et al. 1994; Simons et al. 2000; Meloni-Ehrig et al. 1999).
The occurrence of metastasis and tumor associated mortality in deeply located and
high grade lesions is much higher, whereas the depth and grade of malignancy do not
have the high rate of local recurrence. In addition, tumor associated mortality is notably
increased in cases with local recurrence in less than 12 months (Mentzel et al. 1996; Merck
et al. 1983; Weiss and Enzinger 1977). There is a slight association between histological
tumor grade and proliferating activity, as well as the percentage of aneuploid cells and
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tumor vascularity, but nevertheless, no strong relation with the clinical outcome (Mentzel
et al. 1996, 2001).
1.3.5.6 Angiomatoid Fibrous Histiocytoma (AFH)
Angiomatoid ﬁbrous histiocytoma (AFH) account for about 5% of tumors described as
malignant ﬁbrous histiocytoma and approximately 0.3% of all soft tissue sarcomas. AFH
occur most commonly in children and young adults but other age groups may also be
aﬀected (Argenyi et al. 1988; Fanburg-Smith and Miettinen 1999). There is no clear
gender predilection (Costa and Weiss 1990; Enzinger 1979).
AFH arise most commonly in the extremities, followed by the trunk and head and
neck (Fanburg-Smith and Miettinen 1999).
Only one case of angiomatoid MFH was so far analyzed showing chromosomal aber-
ration. These observed rearrangements include chromosome 2, 12, 16 und 17 as well as
del(11)(q24). Furthermore, translocation on chromosome band 16p11 and 12q13 with
the FUS/ATF1 protein are found (Waters et al. 2000).
Less than 1% metastasis and almost 2-11% recurrence were described in AFH (Costa
and Weiss 1990; Fanburg-Smith and Miettinen 1999). These tumors are generally non-
lethal and have a low mortality due to the late distant metastasis (Costa and Weiss
1990; Enzinger 1979). Furthermore, AFH show no clinical morphological or genetic
factors that predict metastasis (Costa and Weiss 1990; Fanburg-Smith and Miettinen
1999).
1.4 Telomere-maintenance mechanisms in soft tissue
sarcomas
Telomere shortening in consequence of cell division, due to the incomplete synthesis of
linear DNA during replication, plays an important role in both the suppression and
pathogenesis of cancer. Therefore, the activation of a telomere maintenance mechanism
(TMM) is essential for cellular immortalization and thus for long-term tumor growth.
Most human cancers, especially those of epithelial origin, use the activation of telomerase
as their telomere maintenance mechanism, whereas others use an alternative lengthening
of telomeres (ALT) mechanism. The latter one in particular includes subtypes of soft
tissue sarcomas (Henson et al. 2002) and occurs most commonly in tumors with complex
karyotypes, astrocytic brain tumors and osteosarcomas. The prognostic signiﬁcance in
either ALT or telomerase positive tumors varies according to the type of tumor. There-
fore, the characterization and understanding of the telomere maintenance mechanism in
tumorigenesis could have important implications for the diagnosis, treatment and the
development of new strategies for therapy.
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Table 1.9: Telomere sequences and lengths in diﬀerent organisms (modiﬁed by Moon and Jarstfer
(2007))
Group
(Organism)
Telomere length dsDNA Telomere
sequences (5' to 3'
toward the end)
Vertebrate (Human) 5-15 kb TTAGGG
Vertebrate (Mouse) about 30-120 kb TTAGGG
Filamentous fungi (Didymium) 100-400 bp TTAGGG
Ciliate (Tetrahymena) 250-400 bp TTAGGG
Ciliate (Euplotes) exactly 28 bp TTTTGGGG
Higher plant ( Arabidopsis thaliana) 2,5-5 kb TTAGGG(T/C)
Green algae (Chlamydomonas) 300-350 bp TTTAGGG
Insect (Bombyx mori) 6-8 kb TTAGG
1.4.1 Telomeres: A brief insight
Modern interest in telomeres has its roots in experiments carried out by Hermann J.
Müller and Barbara McClintock in the 1930s. Both investigators, working separately
and with diﬀerent organisms, realized that chromosome ends are special structures that
provide stability. The term "telomere", coined by Müller, originate from the Greek for
"end" (telos) and "part" (meros). Hermann J. Müller observed that X-ray irradiation
leads to structural chromosomal changes and that the natural chromosome ends were
never aﬀected in these rearrangements (Müller 1938). In addition, McClintock discov-
ered that without these end caps, chromosomes stick one to another, undergo structural
changes and misbehave in some other ways (McClintock 1941). In 1978, the precise as-
sembling of the telomeres was determined by discovering that telomeres in Tetrahymena
thermophila are composed of an extremely short and simple sequence of Thymines (T)
and Guanines (G) -TTGGGG- repeated 20-70 times (Blackburn and Gall 1978).
1.4.1.1 The telomere sequence
Telomeres are repetitive DNA sequences located at the termini of linear chromosomes of
all mammalian cells, likely of almost all eukaryotes and in a few prokaryotic organism.
The telomere length varies between species from about 300-600 bp in yeast (Shampay
et al. 1984) and up to many kilobases in human (Table 1.9). The mammalian chromo-
somes are composed of linear tandem TTAGGG repeats which in humans are naturally
10-15 kb long (Blasco 2005). However, regardless of arrangements and the number of
telomeric repeats, all telomeres share some characteristics: one strand of the repeated
telomeric DNA sequence is marked by clusters of guanine (G) residues, the so called
G-rich strand and a complementary cytosine (C), C-rich strand. The G-rich strand is
always found at the 3`end of each chromosomal DNA (Klobutcher et al. 1981). The ex-
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Table 1.10: Telomere proteins
Telomere Proteins abbreviation
Telomeric-repeat-binding factor 1 TRF1
Telomeric-repeat-binding factor2 TRF2
TRF1-interacting nuclear factor2 TIN2
TRF2-interacting RAP1 RAP1
Putative telomere-end-binding protein POT1
Binding protein of POT1 TPP1
ception proves the role: Instead of the typical telomeric repeats the species Drosophila
melanogaster, for example, has retrotransposons and the mosquito Anopheles gambiae,
as well as the onion Allium cepa, show complex-sequence tandem repeats (McEachern
et al. 2000).
1.4.1.2 Telomeric proteins and higher order telomere structure
A number of speciﬁc proteins were identiﬁed that directly, or via other proteins, interact
with telomeric DNA. Six of them (Figure 1.1 and Table 1.10) exclusively are dedicated
to speciﬁcally bind to telomeres throughout the cell cycle, and they do not accumulate
or function elsewhere in the nucleus. These are the telomere repeat factor 1 and 2
complexes (TRF1 und TRF2) and the protection of telomeres 1 protein (POT1), which
all bind directly to the double-stranded telomeric repeats. Further proteins of the six,
such as TRF1-interacting nuclear protein 2 (TIN2), do not directly bind to DNA but
nevertheless are components of the regulatory complexes. The TRF1 complex consists
of both TIN2 and POT1 and is involved in telomere-length homeostasis, whereas the
TRF2 complex protects the telomere integrity by remodeling telomeres into telomere-
loops. TRF1, TRF2, POT1 and TIN2, in association with TPP1 and RAP1, have
been detected as a telomeric core, referred to as the shelterin complex with its function
to distinguish their natural chromosome ends from DNA breaks, repress DNA repair
reaction, and regulate telomere-based telomere maintenance. The shelterin complex
and its proteins specially localize to telomeres, and do not function elsewhere in the
nucleus (de Lange 2005; Calcagnile and Gisselsson 2007).
Telomeres and their associated proteins form a higher order structure. Currently two
models are discussed:
 T-loop model (Figure 1.1)
 G-quadruplex structure (Figure 1.2)
As mentioned before (1.4.1.1), human telomeres end in a 150-200 nucleotide G-rich
single-stranded overhang. The G-rich overhang is capable of folding back and annealing
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Figure 1.1: Telomere structure and telomere-associated proteins. a) TTAGGG repetitive se-
quence of mammalian chromosomes that end in a 3`single-stranded overhang. Telomeric DNA is com-
posed of six-proteins (shelterin complex) which are TRF1, TRF2, TIN2, TPP1, RAP1 and POT1. b)
Formation of duplex loops; double stranded DNA is folded in the so called T-loop, while a single-stranded
overhang undergoes limited strand invasion to form the D-loop. (taken from Deng et al. (2008))
Figure 1.2: Models of G-quadruplex structure. left) quadruplex with the phosphate sugar back-
bone ribbon (gray) showing 5`-3`directionality right) G-quadruplex repeats could be stacked 3`to 5`
whereas the upper stack has been rotated relative to the lower quadruplex, with a TTA loop medelled
between the two to link them (taken from Parkinson et al. (2002))
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with the double-stranded region of the TTAGGG repeats to form a telomeric loop (Fig-
ure 1.1), termed T-loop (Calcagnile and Gisselsson 2007; Blasco 2005). As a result, a part
of the strand along the length of the overhang-invasion is displaced and forms a single
strand DNA region which is known as D-loop (Shin et al. 2006). T-loops are composed
of only telomeric sequences and therefore the loop size is proportional to the telomere
length of human and mouse cells. The T-loop structure has been assumed as a mecha-
nism for chromosomal end-protection. These telomere "capping" structures defend the
telomeres from being degraded, fused with one another or recognized as double-stranded
breaks through checkpoints and therefore initiate senescence or apoptosis (Blasco 2005;
Calcagnile and Gisselsson 2007).
Crystal analysis of telomeres resulted in an alternative model, the G-quadruplex struc-
ture (Figure 1.2). The G-rich ends of human telomeres can fold into four-stranded G-
quadruplex structures and can be inter- and intramolecular. The intermolecular quadru-
plexes are formed by two or four separate strands, which associate, whereas the in-
tramolecular quadruplex is formed by either two or four repeats such as the four repeats
in human telomeric DNA (d[AGGG(TTAGGG)3]) (Smith and Feigon 1992; Parkinson
et al. 2002).
Telomeric ends of chromosomes are essential in protecting the cell from recombination
and degradation. Disruption of telomere maintenance potentially inhibits tumor growth,
which can be utilized for developing therapeutic strategies. Furthermore, it was shown
that a quadruplex structure could negatively inﬂuence the telomeric complex which
causes dysfunctional telomeres. (Parkinson et al. 2002; Yanez et al. 2005). Therefore,
the stabilization of telomeric ends as G-quadruplex structures seems to be an approach
in developing new therapeutic strategies. These strategies could destabilize telomere
maintenance in tumor cells. (reviewed in Raymond et al. (2000); Boukamp and Mirancea
(2007)).
1.4.1.3 Telomere length regulation
Telomere length regulation and telomere-length-dependent interaction play a signiﬁcant
role in genomic integrity and were studied extensively in the past. It is known that
critical short telomeres play an important role in genomic instability and therefore in
the pathology of human disease.
But how do critically short telomeres arise? It was believed that all cultured cells were
potentially immortal, as it is the case for several cancer cell lines such as HeLa. In 1961
it was observed by Hayﬂick and Moorhead that normal human diploid ﬁbroblast have
a limited replication capacity (HAYFLICK and MOORHEAD 1961). Human ﬁbroblast
taken from diﬀerent embryonic donors underwent a ﬁnite number of population doublings
(PDs) between 40 and 60, the so called Hayﬂick limit (Hayﬂick 2000). The so called
"Mitotic clock", responsible for the Hayﬂick limit, was unknown until it was shown that
in vitro telomere length decreases with each population doubling (Harley et al. 1990).
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Figure 1.3: Hypothesis of telomere length and its assumed eﬀect Telomere shorten due to the
end-replication problem until they reach the ﬁrst block, known as senescence. Cells undergo senescence
by loss of both p53 and Rb tumor suppressor pathway and continue to divide until they reach the
second block, referred to as crises. Rare cells emerge crises by the activation of a telomere maintenance
mechanism such as telomerase activity or the ALT mechanism. (taken from Nittis et al. (2008))
1.4.1.4 Telomere shortening
At the time of their switch to linear genomes, eukaryotes must have designed a mech-
anism to reorganize their chromosome ends, exhibiting two major problems. The ﬁrst
one is the known end-replication problem. It was proposed independently by Olovnikov
(1971, 1973) and Watson (1972) that DNA polymerase is not able to fully replicate the
linear ends of DNA with each replication cycle. The DNA-replication machineries use
short primers to initiate DNA synthesis. Elimination of the terminal primers at the end
of the lagging-strand leads to a small gap that cannot be ﬁlled. This gap results in the
loss of terminal sequences. The second problem is that cells must distinguish between
their natural chromosome ends and sites of DNA damage in order to avoid checkpoint
activation and inappropriate DNA-repair (de Lange 2004).
Telomere lengths shorten in normal somatic cells after each cell division due to the
inability of the cell to replicate their chromosomes ends completely (Harley et al. 1990).
Furthermore, telomeres below a certain size threshold cause irreversible growth arrest
referred to as replicative senescence. In this state, cells stop dividing but are still viable.
One possibility for cells to bypass senescence is the inactivation of the p53 and Rb tumor
suppressor pathway, resulting in cellular proliferation and further telomere shortening
(Figure 1.3). These cells then reach a second block, which is called crisis and is character-
ized by telomere dysfunction and cell death. The bypass of crisis and the maintenance
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Figure 1.4: Telomerase as ribonucleoprotein complex; telomerase act as reverse transcriptase and
contains an RNA template (TER, blue) and the catalytic protein component (TERT, green) which adds
telomeric repeat sequences to the telomere DNA strand (red) (Telo).
of stable telomere length may be achieved by the activation of telomere maintenance
mechanisms such as the activation of telomerase and/or the alternative lengthening of
telomeres (ALT) (Wei and Sedivy 1999; Shay and Roninson 2004).
1.4.2 Telomerase activity as telomere length maintenance
Telomerase, a large multisubunit ribonucleoprotein complex, is responsible for synthesis-
ing telomeric repeats and thus for telomere length maintenance. Telomerase is a reverse
transcriptase and uses this mechanism to copy an RNA template into DNA. This reverse
transcriptase contains its own template RNA (TR) that, together with a protein compo-
nent (hTERT), constitutes a core enzyme. Telomeric DNA is synthesized by copying an
RNA template sequence de novo in the 5' to 3' direction within the RNA moiety of telom-
erase (Figure 1.4). The over-extension of telomeres is regulated by a multi-component
"telomere homeostasis" system. Interaction among the telomere-associated proteins is
important for this function (Blackburn 1992, 2005)
High levels of telomerase activity are found in cells of the germ line. In these cells it is
essential to maintain stable telomere length for limitless replication. In somatic cells, on
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Figure 1.5: Forms of recombination in ALT (A) Showing telomere-sister chromatid exchanges:(i)
TTAGGG sequence in red, CCCTAA in blue;(ii) second step, semi-conservative DNA replication, dot-
ted lines showing new synthesized DNA;(iii) homologous recombination, (iv) post replicative telomere
exchanges; (B) (i to iv) telomere elongation after strand invasion of a 3'overhang into an adjoining
telomere; followed by elongation of the immigrated strand by DNA polymerase (red dotted line) thus
the C-rich strand can also be ﬁlled; (C) t-loop junction resolution: (i and ii) misarrangement of the
t-loop structure results in free t-circles and segregated telomeres(taken from Cesare and Reddel (2008))
the other hand, telomerase activity was not initially detected, except in lymphopoietic
tissue and regenerative epithelia. Furthermore, telomerase activity was found in all ep-
ithelia along the gastrointestinal tract and the epidermis (Bachor et al. 1999; Taylor et al.
1996). Telomerase activity seems to play an essential role in the lifetime of regenerative
capacity and in normal epithelia.
1.4.3 The alternative lengthening of telomeres (ALT)
The occurrence of alternative lengthening of telomeres (ALT) was ﬁrst observed in some
cell lines, which maintained telomere length over many hundred population doublings
(PDs) in the absence of telomerase (Bryan et al. 1995). This telomerase-independent
mechanism involves extension of telomeric DNA by a recombination-mediated replica-
tion mechanism (Figure 1.5). Fortunately, ALT is generally associated with some pheno-
typic characteristics. One indication of ALT are telomeres that are highly heterogeneous
in length, with some commonly found very long telomeres. Analysis by telomere ﬂuo-
rescence in situ hybridization (FISH) on metaphase spreads shows that in ALT cells,
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telomeres are ranging from less than 2kb to longer than 50kb in length, whereas some
lack any observable telomere signals (Bryan et al. 1995; Henson et al. 2002). Further
studies in ALT cell lines showed that the dynamics of telomere lengths in these cells
are highly complex. Both rapid elongation and rapid deletion events are present in ALT
cells (Murnane et al. 1994). Further it seems that the deletion events generate extra chro-
mosomal telomeric DNA which can be linear (Tokutake et al. 1998; Ogino et al. 1998),
or circular (also known as t-circles Figure 1.5). Particulary, these t-circles seem to be
abundant in ALT cells, therefore becoming another characteristic of the ALT mechanism
(Cesare and Griﬃth 2004; Fasching et al. 2007).
A further phenotypic marker of the ALT mechanism are promyelocytic leukemia nu-
clear bodies (PML), that contain telomeric DNA or proteins, which are termed ALT-
associated PML bodies (APBs) (Yeager et al. 1999). ALT-associated PML bodies are
characterized by telomeric DNA, which colocalizes with the shelterin protein complex or
with DNA repair, recombination or replication factors (Yeager et al. 1999; Henson et al.
2002). Further investigations showed that APBs primarily accumulate linear extrachro-
mosomal telomeric DNA, which presumes that an additional function of APBs is to keep
linear DNA away from being recognized as DNA double strand breaks (DSBs) (Fasching
et al. 2007). All these listed phenotypic hallmarks of ALT are just markers, as it is not
yet known in which way and how tightly they are linked to the ALT mechanism. For
example, some types of glioblastoma multiforme tumors and some cases of soft tissue
sarcomas show neither detectable telomerase activity nor any usual hallmarks of ALT.
1.4.4 Telomere maintenance in soft tissue sarcoma
Telomere maintenance by telomerase, a large ribonucleoprotein complex that connects
hexanucleotide repeats to the telomeres, are most common in tumors of epithelial origin.
The recombination based ALT maintenance mechanism seems to be more frequently
activated in tumors of mesenchymal origin, such as soft tissue sarcomas (see below).
In the last years, much work was done to characterize the telomere maintenance
mechanism in resected lesions. First analyses on this topic was focused on the detection
of telomerase. Later on, the identiﬁcation of ALT led to increased investigation of both
telomerase activity and the ALT mechanism in tumors and cell lines including tumor-
derived cell lines. In recent studies based on the detection of both telomere maintenance
mechanisms in osteosarcomas, a considerable number was found to be ALT positive, at
a frequency of 35% and 47% (Henson et al. 2005; Ulaner et al. 2003). Further studies in
glioblastoma multiforme revealed about 19% of cases using the ALT mechanism, which
is higher than typically seen in carcinomas (about 5-10%) (Hakin-Smith et al. 2003).
Other studies of soft tissue sarcoma subtypes, such as liposarcomas, exhibit the ALT
mechanism at a frequency of 33%, 24% and 24%, observed from 3 independent studies
(Costa et al. 2006; Johnson et al. 2005; Henson et al. 2005). In two of these studies (Costa
et al. 2006; Johnson et al. 2005) about 50% of the investigated liposarcomas showed no
indication of either telomerase or ALT, although telomere maintenance is believed to be
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necessary in tumorigenesis. he activation of a telomere maintenance mechanism remains
a likely contributor to tumor progression as it is important for inﬁnite cell proliferation,
which characterizes most malignancies (Counter et al. 1998).
1.4.4.1 Telomere maintenance: tumor progression and chromosomal instability
in sarcomas
On one hand, recent studies, based on the identiﬁcation of the interrelationship among
telomere maintenance mechanism activation and tumor grade in soft tissue sarcomas,
have shown in liposarcomas that 70% of grade I tumors give no evidence of ALT or
telomerase activation. On the other hand, liposarcomas of grade II and III have shown
typical hallmarks of ALT, telomerase or both mechanisms (Costa et al. 2006). The results
of these studies showed a positive correlation between activated telomere maintenance
mechanism and tumor grade in liposarcomas.
The characterization of both telomere maintenance mechanisms regarding their level
of chromosomal instability revealed marked diﬀerences. Crucial work was done by Scheel
et al. (2001) using both telomere and multiplex ﬂuorescence in-situ hybridization (FISH)
in osteosarcoma-derived cell lines that utilized either ALT or telomerase for their telom-
ere maintenance. Using telomere FISH analysis, ALT positive cells showed telomere
length heterogeneity, dicentric chromosomes and misbehavior in telomere conﬁguration.
Furthermore, analysis of ALT-positive cells by multiplex FISH revealed an increased
number of translocations, deletions and complex rearrangements in comparison with the
telomerase positive cell lines. In a recent study of osteosarcomas by Ulaner et al. (2004),
the authors detected the ALT mechanism in 38 of 60 cases. In contrast, in Ewing's sar-
comas 21 of 30 cases were telomerase positive. The authors have concluded a possible
association between activated telomere maintenance mechanisms and speciﬁc chromo-
somal translocations. Indeed all of the 30 investigated Ewing's sarcomas were positive
for chromosomal translocation whereas the frequency of ALT seems to occur more often
in sarcomas with complex karyotypes. These results are consistent with the ﬁndings
that ALT occurs less frequently in translocation associated sarcomas such as Ewing's
sarcomas or synovial sarcomas (Montgomery et al. 2004).
1.4.4.2 Telomere maintenance in sarcomas: association with patient outcome
As shown before, both mechanisms of telomere maintenance are not equivalent, espe-
cially in their eﬃciency of functional telomere maintenance. Such diﬀerences might have
implication on tumor progression and patient outcome. An interesting study was done
by Hakin-Smith et al. (2003), who examined the eﬀect of telomere maintenance on tumor
behavior in glioblastoma multiforme. This study showed that the median survival of pa-
tients with ALT-positive tumors was about 540 days, while those of non-ALT tumors
was 247 days (median). In addition, tumors of the non-ALT group did not show signiﬁ-
cant changes in the survival rate, if telomerase was expressed. Therefore, in glioblastoma
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multiforme the ALT mechanism might be used as a positive indicator of prognosis. A
related study published by Ulaner et al. (2003) demonstrated the relationship between
telomere maintenance and patient outcome in osteosarcoma. The authors found that
patients without detectable telomere maintenance mechanism have an increased survival
rate (90% ﬁve-year survival). In contrast, tumors positive for ALT, telomerase or both
mechanisms showed a higher mortality (60% 5-year survival). In summary, studies both
from Hakin-Smith et al. (2003) and Ulaner et al. (2003) showed that the association
among the activated telomere maintenance mechanism and patient survival varies de-
pending on the speciﬁc type of malignancy. Since the TMM can vary signiﬁcantly in
soft tissue sarcomas with diﬀerent implications on patient outcome, further studies for
the characterization of the TMM are crucial for developing new strategies for anti-tumor
therapies.
1.4.5 Promyelocytic leukemia nuclear bodies (PML NBs) and its
role in soft tissue sarcomas
The nucleus of mammalian cells is a complex organelle, suborganized into multiple nu-
clear domains and includes a heterogenous family of nuclear bodies such as promyelocytic
leukemia nuclear bodies (PML NBs). The PML nuclear bodies are distinct structures
particulary with regard to the number of diﬀerent proteins containing diﬀerent functions
in the nucleus. PML bodies are shown to be involved in a number of diﬀerent biolog-
ical regulations of the cell such as apoptosis, senescence and DNA damage response
(Figure 1.8). Furthermore, cells that undergo ALT have shown a type of PML nuclear
bodies, which colocalize with telomeric DNA, telomere-associated proteins or proteins
involved in DNA-repair or recombination and are referred to as ALT-associated PML
bodies (Yeager et al. 1999) (see also chapter 1.4.3). PML nuclear bodies are also plays a
role in telomere length regulation in ALT tumors and therefore in soft tissue sarcomas
which use the alternative lengthening of telomere maintenance. In addition, a recent
study of Matsuo et al. (2008) proposed that the presence of PML bodies indicate a poor
prognosis for patients with soft tissue sarcomas such as liposarcomas and malignant
ﬁbrous histiocytomas.
1.4.5.1 Structure and function of PML NBs: a brief insight
PML nuclear bodies were ﬁrst identiﬁed in acute promyelocytic leukemia where the hu-
man PML gene is fused with the retinoic acid receptor alpha(RARA) gene by the t(15;17)
chromosomal translocation (de Thé et al. 1990, 1991). The promyelocytic leukemia pro-
tein PML localizes as punctated structures within the nucleus. A typical number of PML
signals in the human nucleus are 1 to 30 bodies per nucleus with a diameter ranging
between 0.2 to 1.0µm (Bernardi and Pandolﬁ 2007). Number and size of PML NBs
are dependent on diﬀerent factors such as cell cycle phase, cell type and diﬀerentiation
stage (Dellaire and Bazett-Jones 2004). PML NBs are dynamic structures that move
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Figure 1.6: Illustration of post-translational modiﬁcations of PML. Demonstration of the
protein promyelocytic leukemia (PML) with its functional sites; Several kinases such as extracellular-
regulated kinase (ERK), checkpoint kinase-2 (CHK2), ataxia telangiectasia mutated (ATM)- and RAD3-
related (ATR) and casein kinase-2 (CK2) are known to phosphorylate PML at the three sumoylation
sites (S) or the SUMO-binding domain of PML. All post-translational modiﬁcations occur in the con-
served region of the protein and, therefore, are common in all PML isoforms. (taken form Bernardi and
Pandolﬁ (2007))
Figure 1.7: ThePML gene and its protein isoforms The gene PML contains approximately 53.000
bases and nine exons. All isoforms contain exon 1 to 3 and the seven subgroups are generated by
alternative splicing of exon 7 to 9 at the C-terminal end. Further splicing variants between exon 4,5
and 6 has been reported to result in cytoplasmic PML proteins, as exon 6 contains the nuclear location
signal (NLS) (taken from Bernardi and Pandolﬁ (2007))
33
1 General Introduction
Figure 1.8: Promyelocytic leukemia nuclear bodies and its many functions PML NBs are struc-
tures that are involved in several cellular functions such as DNA-damage response, apoptosis, cellular
senescence and angiogenesis. Further functions which are regulated by PML NBs are: identiﬁcation
and storage of proteins; post-translational modiﬁcations of proteins and regulation of nuclear activities
such as transcriptional regulation and chromatin organization. However, it is not yet known whether
PML NBs regulate such diﬀerent function or whether there is functional heterogeneity. The functional
heterogeneity of PML might be dependent on position in the nucleolus relating to chromatin or spe-
cial compartments, or may depend on the biochemical arrangement (taken from Bernardi and Pandolﬁ
(2007)).
within the nucleus and are tightly bound to the nuclear matrix. Studies by electron
microscopy have shown that PML NBs are composed of a ring-like protein structure
without detectable nucleic acids in the center of the ring. At the periphery of the ring
PML NBs are in contact with chromatin ﬁbres. The interaction with chromatin ﬁbres
is suggested as a mechanism for stabilization of PML NBs position in the nucleus. Fur-
thermore, localization to other nuclear structures seems also not to be random (Borden
2002; Grande et al. 1996). The work of Görisch et al. (2004) have impressively shown
that nuclear bodies such as PML and Cajal bodies diﬀuse within an chromatin corral
whereas these chromatin corrlas move within the nucleus.
PML and its constitutive component Sp100 seem to be highly modiﬁed by SUMO (=
small ubiquitin-related modiﬁer) (Seeler and Dejean 2003). The protein PML contains
three SUMO modiﬁcation sites and one SUMO interaction motif as demonstrated in
Figure 1.6. Not only PML NB but also a number of PML NB components are sumoylated
or bind to SUMO, demonstrating the important role of SUMO in PML NB formation.
Furthermore, the protein PML includes a N-terminal RING ﬁnger, two B -boxes and a
leucine-rich-coiled-coiled domain, which are encoded by exon 1 to 3 of the PML gene and
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belong to the RBCC family (Fagioli et al. (1998); Jensen et al. (2001)). The gene PML
is located on chromosome 15q22 and contains nine exons, whereas alternative splicing of
the C-terminal exons leads to generation of the PML isoforms I-VII, which are shown in
Figure 1.7 (Jensen et al. 2001). Most isoforms are predominantly located in the nucleus
due to the nuclear localization signal (NLS) added by exon 6. (Condemine et al. 2006).
However, it has been suggested that diﬀerent PML isoforms bind to speciﬁc interaction
partners and thus perform specialized function. Individual expression of single PML
isoforms in the cell, where several isoforms are expressed in combination, contributes
to a special PML NB structure. The cellular function of PML NBs has focused on the
identiﬁcation of proteins that bind to these structures. As a result, many proteins were
found to localize to PML NBs partially or temporally with the consequence that PML
has been implicated in several biological functions as shown in Figure 1.8. The distinct
nature of the proteins that accumulate in PML NBs has made it diﬃcult to deﬁne the
function of PML and its related structures. Currently, just a few models try to explain
the biological function of PML (Dellaire and Bazett-Jones 2004; Borden 2002; Zhong et al.
2000b). A ﬁrst model proposes that PML NBs act as nuclear storage for the aggregation
of proteins involved in both pathological or normal situations. In a second model, PML
NBs operate as a catalytic surface for proteins, where they accumulate and are modiﬁed
after translation. Another proposed function of PML is an active platform for speciﬁc
functions of the nucleus such as transcription or chromatin regulation. Further studies
on PML NBs in the future will be crucial to conﬁrm or to regenerate these models.
Although recent studies suggested that PML nuclear bodies may be heterogenous in
composition, mobility and function, open questions remain such as: How can a single
protein carry out so many functions and what is the evolutionary advantage? (Bernardi
and Pandolﬁ 2007).
1.5 Aim of the project
Human tumors maintain an indeﬁnite replicative potential through the activation of
telomere maintenance mechanisms. Telomerase activity is the most common mechanism
used to maintain telomeres. A number of tumors was shown to maintain telomeres
by a recombination-based mechanism that has been termed alternative lengthening of
telomeres (ALT). In particular, ALT tumors mainly include speciﬁc subtypes of soft
tissue sarcomas associated with complex karyotypes.
Aim of the thesis was:
 evaluation of the frequency distribution between ALT-positive and telomerase pos-
itive tumors in diﬀerent subgroups of soft tissue sarcomas
 correlation of the telomere maintenance mechanisms with number of imbalances
(CGH) with the intention to determine, whether the activation of a telomere main-
tenance mechanism associates with speciﬁc genetic alterations
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 development of an spot analyses program for automatic quantiﬁcation of colocal-
izations in multi-channel 3D microscopy images, to quantify a large number of
tumors by ALT-associated PML bodies and telomere size distribution
 investigations of PML nuclear bodies in order to study whether one of the PML
isoforms preferentially bind to telomeres in ALT positive cell lines
Since the telomere maintenance mechanism (TMM) can vary signiﬁcantly in soft tis-
sue sarcomas, the characterization of these malignancies and their TMM is crucial for
developing new strategies for anti-tumor therapies.
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The work of the manuscript "Frequency distribution of TMM in soft tissue sarcomas"
(in preparation) was performed by the author Petra Sander and include: writing of the
whole manuscript; preparing of the Figures 2.1, 2.2, 2.3, 2.4, 2.5, 2.8, 2.9, 2.10, 2.11, 2.12
and Table 2.1; establishment of the combined telomere ﬂuorescent in situ hybridization
and PML immunoﬂuorescence; staining procedures of all investigated samples; took all
confocal images of tumor samples and non-tumor samples and prepared them for analyses
(see chapter 2.2); had the idea for the automatic quantiﬁcation of the ALT-mechanism;
brought all data sets together (including TRAP analyses, CGH data, detection of ALT
markers), interpreted them and prepared the data for further correlation analyses.
The work of the manuscript (chapter 2.2) "3D Geometry-Based Quantiﬁcation of Colo-
calizations in Three-Channel 3D Microscopy Images in Soft Tissue Tumors" has been
done in cooperation with Stefan Wörz (Dept. Bioinformatics and Functional Genomics,
Biomedical Computer Vision Group, University of Heidelberg, BIOQUANT, IPMB, and
DKFZ Heidelberg). The author of this thesis (Petra Sander) was involved in this work
by: initiating the contact to Stefan Wörz; had the idea for automatically analysis of
markers for the ALT-mechanism of confocal images (stacks); wrote the biological part
of introduction in the manuscript; took and provided all confocal images which were
used to develop the software; did the veriﬁcation of the single spot analyses and DAPI-
segmentation and deﬁned the parameter settings for image analyses by this programm;
set the threshold for very large telomeres; suggested the diﬀerent types of colocaliza-
tions and has been involved in many discussion that addressed the development of the
automatic quantiﬁcation of the confocal images, such as the quantiﬁcation of very large
telomere spots. This manuscript is accepted for the SPEI conference (February 13-18,
2010 in San Diego, California USA). A shorter version of this manuscript is also accepted
for the Workshop "Bildverarbeitung für die Medizin (BVM 2010, Aachen, Germany) and
a longer version is submitted for a Special Issue on Multivariate Microscopy Image Anal-
ysis in IEEE Transactions on Medical Imaging. Unpublished data which included the
veriﬁcation of the program in chapter 2.2.6 was written by author of this thesis (Petra
Sander) and Figures were provided by Stefan Wörz.
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2.1.1 Abstract
The activation of a telomere maintenance mechanism (TMM) is considered essential for
cellular immortalization, and thus for long-term tumor growth. Most human cancers,
especially those of epithelial origin, use the activation of telomerase as their telomere
maintenance mechanism; others tumors displayed an alternative lengthening of telom-
eres (ALT) mechanism. The latter particularly includes subtypes of soft tissue sarcomas.
Here, we assessed the frequency distribution of telomere maintenance within diﬀerent
subgroups of soft tissue sarcomas. In order to assay the ALT-mechanism, we quantiﬁed
markers of ALT, namely the occurrence of ALT-associated PML bodies (APBs) and
telomere length distribution. TRAP assay was performed in order to determine telom-
erase activity. In our ﬁndings, a high level of telomerase correlates inversely with both
the occurrence of large telomeres and APBs. Comparative genomic hybridization (CGH)
analyses revealed in telomerase and ALT-positiv tumors speciﬁc genetic alterations (p<
0.05). The level of genomic instability occurred similarly in both ALT-positive soft tis-
sue tumors and telomerase positive tumors. Nevertheless, tumors with an incidence for
ALT compared with tumors possessing telomerase activity showed reciprocal alterations
at the same chromosome bands. This study suggests several genomic regions involved
in the regulation of telomere maintenance mechanisms and might lead to new markers
or targets for anti-cancer strategies.
2.1.2 Introduction
The transformation from normal to malignant cells is a multistep process, and includes
accumulations of genetic changes (Batista and Artandi 2009). Telomere dysfunction is
likely to be involved in genomic instability by inducing chromosomal rearrangements
which can provide the genetic basis for tumor progression (Batista and Artandi 2009;
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Blasco 2005).
Human telomeres are the ends of the chromosomes and are composed of the repet-
itive non-coding sequence TTAGGG, which, are 10-15kb long and end in a 150-200
nucleotide G-rich single stranded overhang (Blasco 2005). This G-rich overhang is ca-
pable of folding back and annealing with the double-stranded region of the TTAGGG
to form the telomeric loop, termed T-loop (Blasco 2005). Consequently, a part of the
strand along the length of the overhang-invasion is displaced and forms a single strand
DNA region, which is referred to as the D-loop (Denchi 2009; de Lange 2002). The T-
loop formation and special proteins bound to telomeric DNA has a putative important
function: to protect chromosome-ends from being degraded, fused with one another or
being recognized as double-stranded breaks through cell cycle checkpoints, which would
initiate senescence or apoptosis (Blasco 2005). Speciﬁc proteins have been found that
interact with telomeric DNA either directly or via other proteins, and are essential for
proper telomere function (de Lange 2005). Six of them exclusively localize to telomeres
throughout the cell cycle to form, the so called shelterin complex, and they do not accu-
mulate or function elsewhere in the nucleus. These are TRF1, TRF2 (Telomeric Repeat
binding Factor1 and 2) TIN2 (TRF1- and TRF2- Interacting Nuclear Factor 2), POT1
(Protection of Telomeres 1), TPP1 and RAP (Repressor/Activator Protein1). Other
proteins were observed to be involved in mammalian telomere protection, which interact
with the chromosome ends transiently and non-exclusively. Examples include the Mre11
complex which is involved in homologous recombination of double stranded breaks, and
XPF/ERCC1, which are involved in nucleotide-excision repair (Denchi 2009). Telomere
length shortening occurs in normal somatic cells after each cell division due to the inabil-
ity of the cells to replicate their chromosomes end completely, which is also known as
the end-replication problem (Blasco 2005). Furthermore, telomeres below a certain size
cause an irreversible growth arrest, referred to as replicative senescence. One possibility
for cells to bypass senescence is the inactivation of the p53 and Rb tumor suppressor
pathway, resulting in cellular proliferation upon further telomere shortening. These cells
then reach a second proliferation block called crisis which is characterized by telomere
dysfunction and cell death (Wei and Sedivy 1999; Shay and Roninson 2004). With
respect to tumor biology, critically short telomeres lead to contradicting consequences.
On the one hand, telomere dysfunction can trigger a DNA damage response resulting in
apoptosis and senescence and act, therefore, as a tumor suppressor mechanism (Denchi
2009). On the other hand, dysfunctional telomeres are thought to be the initiator for
end-to-end fusion, leading to the breakage-fusion-bridge (BFB) cycle, which is charac-
terized by chromosomal breakages, resulting in chromosomal loss or ampliﬁcation and
ﬁnally the generation of numerical and structural chromosomal aberrations (Denchi 2009;
Boukamp et al. 2005). These aberrations, in turn, can aid in tumor development.
Cancer cells bypass crisis by maintaining stable telomere length through the activa-
tion of a telomere maintenance mechanism, which permits limitless replicative poten-
tial. Most human cancers, especially those of epithelial origin, activate the canonical
telomerase (a large ribonucleoprotein complex) pathway. However a small number of tu-
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mors (10%), use the alternative lengthening of telomeres. The occurrence of alternative
lengthening of telomeres (ALT) was ﬁrst observed in some cell lines which maintained
telomere length over hundreds of population doublings in the absence of telomerase ac-
tivity (Bryan et al. 1995). This telomerase-independent mechanism involves extension of
telomeric DNA by a recombination-mediated replication mechanism. ALT is generally as-
sociated with certain phenotypic characteristics, such as highly heterogeneous telomeres
in length, ranging from less than 2kb to longer than 50kb in length, while some chromo-
somes lack any observable telomeres (Bryan et al. 1995). Another phenotypic marker for
ALT is the association of promyelocytic leukemia nuclear bodies (PML) with telomeres,
termed ALT-associated PML bodies (APBs) (Yeager et al. 1999). These APBs are char-
acterized by telomeric DNA, which colocalizes with shelterin or DNA repair proteins, as
well as with recombination or replication factors (Jiang et al. 2005, 2007). These hall-
marks of the alternative lengthening of telomeres seem to be more frequently present in
tumors of mesenchymal origin, such as soft tissue sarcomas.
Soft tissue sarcomas include a heterogeneous group of mesenchymal tumors and can
be subdivided into two groups based upon their cytogenetic aberrations. The ﬁrst group
is characterized by simple, near-diploid karyotypes and speciﬁc translocations. Ewing's
sarcomas, alveolar rhabdomyosarcoma, and synovial sarcomas belongs to this group.
The second group displays complex karyotypes and includes, malignant peripheral nerve
sheath tumors (MPNST), liposarcomas and malignant ﬁbrous histiocytomas (MFH)
(Larramendy et al. 1997; Helman and Meltzer 2003).
In this study the occurrence of ALT was assessed in subgroups of soft tissue sar-
coma (STS) such as leiomyosarcomas (LMS), malignant peripheral nerve sheath tumors
(MPNST), malignant ﬁbrous histiocytoma (MFH), synovial sarcomas (SS), pleomorphic
liposarcomas (PLLS), myxoid round cell liposarcoma (MRCLS) and dediﬀerentiated li-
posarcoma (DDLS).
2.1.3 Material and Methods
2.1.3.1 Tumor and tissue material
The investigated tumor samples were collected between 1991 and 2008 at the Institute of
Pathology, University of Heidelberg, Germany. Non-tumor tissue samples were collected
and provided 2008/2009 at the National Center for Tumor Diseases (NCT), Heidel-
berg. Skin sections from healthy donors and ﬁbroblast cell lines were provided by Petra
Boukamp (German Cancer Research Center). Tumor tissues from surgical specimens or
biopsies were snap-frozen in liquid nitrogen within 30 min after surgical removal and
stored at -196°C until use. Before further use, cryo-sections of 4-6µm thickness were
prepared and stained with hematoxylin and eosin. Only tissue samples that contained
at least 80% of tumor cells were used for further experiments.
40
2.1 Frequency distribution of TMM in soft tissue sarcomas (in preparation)
2.1.3.2 Telomere Repeat Ampliﬁcation Protocol (TRAP)
Cell lysis of tumor- and non-tumor tissues and telomerase assay were performed using
the TRAPeze kit (Q-Biogene, Heidelberg, Germany) according to the manufacturers
recommendations.
2.1.3.3 Quantiﬁcation of colocalization in three-channel 3D microscopy images
For automated image analysis a program called CellSegmentation was used, which was
especially designed for this approach. (see chapter 2.2). In brief: To segment the DAPI-
stained cell nuclei, we applied 3D median and Gaussian ﬁlters for noise reduction with
subsequent Otsu thresholding for segmentation of nuclei and non-nuclei compartments.
To detect structures such as telomere- and PML-"spots", coarse center positions of
"spots" were determined by detection of intensity maxima. In the next step, each
detected spot candidate is quantiﬁed by the 3D intensity proﬁle with an underlying
Gaussian function. To determine colocalizations between telomeres and endogenous
PML, we utilized the geometry of the structures based on the ﬁtting results, i.e. 3D
position, 3D orientation and 3D shape. A colocalization was deﬁned as an (partial)
overlap of two or more structures from the diﬀerent channels using the geometry of
these structures. Due to the geometric representation of those structures with sub-voxel
resolution we were able to diﬀerentiate between diﬀerent types of colocalization (see
chapter 2.2).
2.1.3.4 Comparative genomic hybridization (CGH)
DNA extraction of frozen tumor samples was performed as described previously (Joos
et al. 1995, 1996). Tumor DNA was isolated from 20 µm tissue sections using proteinase
K digestion (2 mg/ml in 50 mM Tris-HCL, 1 mM EDTA, 0.5% Tween 20) followed by
ethanol precipitation. Control DNA was isolated from placenta tissue. Tumor DNA was
labeled using 16-dUTP (Roche) and control DNA was labeled with Digoxigenin-11-dUTP
(Roche Mannheim, Germany) using nick translation according to the manufacturers
instructions. Approximately, 1µg of biotin-labeled tumor DNA, 1 µg of digoxigenin-
labeled control DNA and 50µg Cot-1-DNA (Gibco/BRL, Geithersburg, MD, USA) were
denaturated at 75°C for 6 min and pre-annealed at 37°C for 30 min. The DNA was then
added to normal metaphase slides (Vysis, Downers Grove, IL, USA) which had been
denatured in a heat block at 75°C for 7 min followed by 37°C for 20 min. Hybridization
was performed in a humid chamber at 37°C for 48 hours. Afterwards, several post-
hybridization washes and detection of hybridized DNA by ﬂuorescein and rhodamine
were performed. Image analysis was carried out by a epiﬂuorescence microscopy (Zeiss,
Wetzlar, Germany) with a charged couple device (CCD) camera, and the CytoVision
software 3.52 package (Applied Imaging, Sunderland, UK) or the ISIS CGH software
package (MetaSystems, Altlußheim, Germany). Gray level images of 10-15 metaphase
spreads were recorded separately for each ﬂuorochrome and the ratio of FITC: TRITC
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ﬂuorescence intensities along each individual chromosome were calculated and averaged.
Chromosomal imbalances were detected by ratio proﬁles deviating from the balanced
value of 1.0 with the values of 1.25 and 0.75 as diagnostic cutoﬀ levels for over- and
underrepresentation of chromosomal material, respectively had been thoroughly tested
in numerous studies and provided a robust diagnostic criteria. To avoid false positive
results in critical chromosomal regions, such as the pericentromeric subregions 1q11-q12,
9q11-q12 and 16q11.1-11.2, chromosome subregion 1p32 as well as chromosomes 19 and
Y, these regions were excluded from the analysis.
2.1.3.5 Statistical Analysis
The correlation between telomerase expression level (TRAP), ALT markers and genetic
stability at selected chromosome bands was tested using permutation testes for testing
independence in two-way contingency tables (Hothorn et al. 2008). A permutation ver-
sion of Jonckheere's trend test (Jonckheere 1954) was used to test for changes in the
total number of aberrations (gains/losses) with respect to telomerase expression and
ALT markers level. All analyses were exploratory. Therefore no p-value adjustment for
multiple testing was done. A result was considered as statistical signiﬁcant if the P
value of the corresponding test statistic was smaller than 5% (p < 0.05). All statistical
computations were performed using R (R Development Core Team 2008), version 2.7.2
and R packages coin, version 0.6-9 and clinfun, version 0.8.2.
2.1.3.6 Fluorescence microscopy
3D ﬂuorescence signals were detected in Z-stacks of about 10 to 30 frames with 0.28 µm
spacing by confocal laser scanning microscopy (TCS SP2 Leica Microsystems, Germany).
The PML nuclear bodies were detected by immunolocalization of PML PG-M3 (mouse
monoclonal, Linaris; dilution 1:200). The secondary antibody used as a reporter was
tagged with FITC (Linaris, Germany; dilution 1:200). The telomeres were identiﬁed by a
Cy3-labeled (CCCTAA)3 peptide nucleic acid (PNA) probe (Dako, Dennmark). For com-
bined telomere-FISH and PML immunoﬂuorescence, cells were ﬁxed on glass slides with
3.7% formaldehyde (freshly prepared, J.T.Baker) in PBS (phosphate-buﬀered saline).
After ﬁxation, the specimens were washed in PBS. The slides were then dehydrated by a
series of ethanol washes (70%, 90%, 100%), each incubated for 2 min, and brieﬂy air dried.
Eight µl of Cy3-labeled PNA probe was added and then denatured for 3 min at 80°C.
After hybridization for 2 h at room temperature, the slides were washed several times
at room temperature with 70% formamide/ 10 mM Tris-HCL, pH 7.2 (25 min), PBS
(30 sec), 0.1 SSC for 5 min at 65°C, and PBS containing 0.05% Tween-20 (2 x 5 min at
room temperature). After telomere-FISH, the specimens were permeabilized by incuba-
tion with 0.02% Triton X-100 (Sigma) in PBS for 3 minutes at room temperature. Then,
a protein block was applied by incubation with 4% goat serum in PBS for 10 minutes.
Antibodies, diluted in PBS containing 1% goat serum, were incubated for 30 minutes at
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37°C (ﬁrst antibody), and at room temperature (second antibody). Each antibody incu-
bation was followed by three washes with PBS. Finally, slides were covered with 1 drop of
antifade solution (VectaSield, Linaris) containing 4,6-Diamidino-2phenylindole (DAPI).
Images were processed using MacBiophotonics ImageJ and subsequently exported and
saved as either jpg- or tiﬀ-ﬁles.
2.1.4 Results
2.1.4.1 Frequency distribution of telomerase expression levels in subgroups of
STS
Since the telomere maintenance mechanism can vary signiﬁcantly in soft tissue sarco-
mas (STS), we evaluated the frequency distribution of telomerase activation and ALT-
mechanism in diﬀerent soft tissue sarcoma entities. To investigate the regulation of
telomerase in soft tissue sarcoma subtypes in more detail, we determined the telomerase
status by TRAP assay. As shown in Figure 2.1, telomerase activity in diﬀerent tumor
samples varies from none or moderate (0 or 1) to high levels (2). HaCaT immortalized
keratinocytes were used as a control for cells with high telomerase activity. In Figure 2.2,
it is shown that telomerase activity varies signiﬁcantly, from 100% (TRAP1 + TRAP2)
in synovial sarcomas to about 46% in pleomorphic liposarcomas. In addition, our ﬁnd-
ings indicate that the expression levels of telomerase diﬀer with diﬀerent subtypes of soft
tissue sarcoma (Figure 2.2). Furthermore, all tumor samples with speciﬁc translocations
such as MRCL (myxoid round cell liposarcomas) and SS (synovial sarcomas) show an
up-regulated telomerase activity compared to tumors with non-speciﬁc translocations,
like pleomorphic and dediﬀerentiated liposarcomas (Figure 2.2). These data suggest that
soft tissue sarcomas with speciﬁc translocations are more prone to expressing telomerase
than tumors with complex karyotypes.
2.1.4.2 Correlation of telomerase expression level and markers for ALT-like STS
In order to study whether or not, these tumors show evidence of both ALT and telom-
erase activity, we combined telomere ﬂuorescence in situ hybridization and PML im-
munoﬂuorescence to detect ALT-associated PML bodies and heterogeneous telomere
length distribution within the same tumor samples (Figure 2.3). Using confocal laser
scanning microscopy, images were acquired from three independent regions of each sam-
ple, and were analyzed using an image analysis program (see chapter 2.2) designed
exclusively for this approach. The colocalization of PML with telomeres were allocated
to one of three types; the colocalization type Col 1 (Col 1 equates to c1 compare chapter
2.2) is where a telomere signal is fully within a PML nuclear body. In Col 2 (Col 2
equates to c3 compare chapter 2.2), both spots overlap and the center of each spot is
located within the other spot. Both colocalization types are each an indication for ALT-
associated PML-bodies. The third type, Col 3 (Col 3 equates to c7 compare chapter
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Figure 2.1: Diﬀerent telomerase expression level in STS revealed by TRAP-assay. (A)
Telomerase activity was determined by TRAPeze assay in subgroups of soft tissue sarcoma, most of
which exhibit diﬀerent telomerase expression levels (no, moderate and high), an example is shown in
(A). Each column display a diﬀerent tumor sample. HaCaT cells were used as positive control (data not
shown in example A). (B) Fibroblasts, diluted buﬀer and HaCaT cells treated with RNase were used
as negative control. In titration experiments, dilutions of 500ng, 50ng and 5ng of HaCaT extracts were
compared with diluted extracts from all investigated soft tissue sarcomas (e.g. a, b and c). In order to
study the regulation of telomerase in soft tissue sarcoma subtypes in more detail, we determined the
telomerase status by TRAP assay. Telomerase activity varies from none/low to high levels (TRAP 0 =
no telomerase activity, TRAP 1 = low/ moderate telomerase activity and TRAP 2 = high telomerase
activity)
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Figure 2.2: Diﬀerent telomerase expression level in STS revealed by TRAP-assay. TRAP
activity varies signiﬁcantly, from 100% in synovial sarcoma to about 46% in pleomorphic liposarcomas.
These data show that the expression levels are characteristic for diﬀerent subtypes of soft tissue sarcoma.
Zero telomerase expression level is shown in blue, moderate in red, and high in green. Total number
of investigated samples are shown in parentheses. MCLS and SS belong to the group of translocation
associated sarcomas, whereas the others exhibit a complex karyotype.
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Figure 2.3: Images of soft tissue sarcomas exhibiting diﬀerent TMM. ALT-associated PML
bodies (APBs) and heterogeneous telomere spot size distribution with exceptionally long telomeres
(VLT) were detected by combined telomere ﬂuorescence in situ hybridization (red staining) and PML
immunoﬂuorescence (green staining) in frozen sections of diﬀerent soft tissue sarcoma subgroups. Nuclei
were counterstained with 4',6-diamidino-2-phenylindol. Using confocal laser scanning microscopy, 3D
images were acquired from three independent regions of the tumor marked by A, B and C. Shown
are examples of diﬀerent cases; leiomyosarcomas (LMS13 and LMS1), dediﬀerentiated liposarcoma
(DDLS2) and malignant ﬁbrous histiocytoma (MFH3), which exhibited diﬀerent variations of telomere
maintenance mechanisms (TMM)
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Figure 2.4: Correlation of telomerase expression level and markers for ALT Correlation of
telomerase expression level with ALT-associated PML bodies (APBs) and very large telomeres (VLT)
in all investigated soft tissue sarcoma subgroups. Telomerase activity was detected by TRAP and
labeled either by 0, 1, 2. 0 denotes no, 1= low/moderate and 2 = high telomerase activity. Colocal-
izations (APBs) Col 1 are sub-grouped into 0, 1 and >1, which denotes none, one and more than one
colocalization per sample respectively; Col 2, Col 3 and VLT (verly large telomeres) are each subdivided
into 0, 1-3 and >3: denoting respectively none, 1 to 3 and more than 3 of Col 2, Col 3 colocalization or
VLT spots per sample.
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Figure 2.5: Correlation of telomerase expression level and markers for ALT. Correlation of
telomerase expression level with ALT-associated PML bodies (APBs) and very large telomeres (VLT)
relating to the investigated subgroups of soft tissue sarcomas (synovial sarcoma, malignant peripheral
nerve sheath tumors, leiomyosarcomas, malignant ﬁbrous histiocytomas, myxoid round cell liposarco-
mas, dediﬀerentiated liposarcomas and pleomorphic liposarcomas). Telomerase activity detected by
TRAP and subdivided into 0, 1, 2. O being no, 1= moderate and 2 = high telomerase activity. Colocal-
izations (APBs) labeled by Col 1 with 0, 1 and >1 denotes none (0), one (1) and more than one (>1)
colocalization per sample respectively; Col 2, Col 3 and VLT (verly large telomeres) are subdivided into
0, 1-3 and >3: to indicate none (0), 1 to 3 (1-3) and more than 3 (>3) colocalization of Col 2, Col 3 or
VLT spot per sample
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2.2), denotes the colocalization of a PML spot with telomere spots that are exceptionally
long. Using the same program and images, we identiﬁed a heterogeneous telomere size
(very large telomeres) by the quantiﬁcation of telomere signal sizes. To compare the
detected amount of Col 1, Col 2 and Col 3 and very large telomeres (VLT) within the
nuclei of diﬀerent tumor samples for statistical correlations, we performed segmentation
of the nuclei based on DAPI-staining. The total amounts of analyzed Col 1, Col 2 and
Col 3 co-localizations as well as very large telomeres were normalized to 10,000 µm3
of the segmented DAPI-channel. Furthermore, for the Col 1 colocalization, we distin-
guished between none (0), one (1) and more than one (>1) colocalizations per tumor
sample. For Col 2 and Col 3, we distinguished between no (0), 1-3 and more than 3 (>
3) colocalizations per investigated tumor sample. For very large telomere (VLT) spots,
we distinguished between no (0), 1-3 and more than 3 (> 3) spot per sample. Further
correlation of the telomere maintenance mechanisms include just tumors samples which
are also analyzed by CGH. Therefore the number of tumor samples is lower (104 cases
instead of 130 cases) when compared to those cases analysed by diﬀerent expression level
of telomerase, as demonstrated in Figure 2.2. As shown in Figure 2.4, a total of 104
soft tissue sarcomas were investigated for any correlation between telomerase expression
levels and the abundance of APBs and very large telomeres (VLT). Statistical analysis re-
vealed a signiﬁcant correlation between telomerase expression levels and the abundance
of markers for ALT (correlation of TRAP results and Col 1, p = 0.01, with Col 2, p =
0.002, with Col 3, p <0.0001 and with VLT, p <0.0001). As displayed in Figure 2.4,
tumor samples with moderate telomerase expression levels showed an increased number
of APBs and very large telomere spots compared to those tumors without telomerase
activity. Furthermore, the number of ALT-markers again decreases signiﬁcantly in sam-
ples with high telomerase expression level. These ﬁndings could not be conﬁrmed for
each subtype of soft tissue sarcoma, as the number of samples in each subgroup was
too small to achieve a robust statistical result. Nevertheless, all investigated subgroups
of soft tissue sarcomas showed a diﬀerent signature with regard to their telomerase ex-
pression levels, number of APBs, and very large telomeres (Figure 2.5). In all diﬀerent
subgroups we observed that in tumors with high telomerase expression (TRAP2), the
number of APBs and very large telomeres decreased. Furthermore, soft tissue sarcoma
subtypes, such as synovial sarcoma and myxoid round cell liposarcomas, having speciﬁc
translocations, had no heterogeneous distribution of telomere length (VLT) even when
the tumors showed a moderate telomerase expression level (see MRCL in Figure 2.5).
Our results revealed that high expression levels of telomerase might suppress the appear-
ance of ALT-associated PML bodies but even more the distribution of heterogeneous
telomere size. Besides high telomerase expression, our data showed that soft tissue tu-
mors with speciﬁc translocations were associated with a decreased number of very large
telomeres.
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Figure 2.6: No correlation between genomic instability and telomerase expression The y axes
represent the values of either gains or losses per investigated tumor sample (0.5 equates to 50%). The
x axes labeled 0, 1, 2, denote 0= no, 1= low/moderate and 2 = high telomerase activity; p-values are
shown within the box-plots.
2.1.4.3 Identiﬁcation of genomic instability in tumors with telomerase
expression and ALT-like tumors
To identify whether there is a correlation between telomere maintenance mechanisms
(TMM) and genetic alterations, we performed CGH and analyzed the same fresh frozen
tissue specimens of soft tissue sarcoma previously studied for the TMM distribution.
To evaluate the ALT-mechanism in respect to genetic alteration, APBs and telomere
size distribution were used in the same way as before in studying TMM distribution. As
shown in Figure 2.6, there are no signiﬁcant diﬀerences regarding the number of imbal-
ances, including gains and losses (p = 0.39 and 0.67, respectively), when compared to
tumors showing elevated telomerase expression levels. Therefore, there is no evidence
that those tumors with high telomerase expression levels exhibit fewer genomic imbal-
ances compared to tumors without telomerase activity. I cannot be concluded that the
maintenance of telomeres by telomerase prevents genomic instability.
Similar ﬁndings are observed for the ALT mechanism markers (Figure 2.7) such as
Col 1 and Col 3 colocalization, as well as very large telomeres. These markers show
no signiﬁcant changes with regard to chromosomal gains and losses compared of those
tumors without markers for ALT. However, there is an exception which comprises APBs,
deﬁned by Col 2 colocalization. This type of colocalizations show signiﬁcantly (p =
0.036) more chromosomal gains with an increase in number of these colocalizations.
2.1.4.4 Telomerase and ALT-positive tumors reveal speciﬁc genetic alterations
CGH analysis is a robust method to characterize chromosomal imbalances. As shown
in Table 2.1, analysis by CGH has shown that TMM correlates with speciﬁc genetic
aberrations and these correlations are statistically signiﬁcant (p < 0.05). The most
frequent over-representations aﬀecting chromosome bands (p < 0.05) in tumors with high
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Figure 2.7: No correlation between genomic instability and ALT The y axes represent the values
of either gains or losses per investigated tumor sample (0.5 equates to 50%). The x-axes for Col 1 labeled
with 0, 1 and >1 denotes none (0), one (1) and more than one (>1) Col 1 colocalization per sample;
Col 2, Col 3 and VLT (very large telomeres): subdivided into 0, 1:3 and > 3, indicate non (0), 1 to 3
(1:3) and more than 3 (>3) of Col 2, C 3 colocalization or VLT per sample; p -values are shown within
the box-plots
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Table 2.1: Chromosome bands with signiﬁcant alteration in respect to TMM (p<0.05)
Markers for telomere
maintenance
mechanisms
Chromosome bands
with signiﬁcant
alteration (P<0.05)
Telomerase expression 1p12; 1p13; 1p21; 1q32; 1q41; 2p23; 2p24; 2p25;
2q33; 2q34; 2q35; 4p15; 4p16; 5p15; 8q22; 8q23; 8q24;
11p12; 11p13; 11p14; 11p15; 11q11; 11q13; 11q14; 11q21
11q22; 17p13; 20q11; 20q12; 20q12; 20q13
Col 1 colocalizations (APBs) 1p12; 1p13; 1p21; 1p22; 1q32; 1q44; 2q32; 2q33
4p14; 4p14; 4q28; 6q26; 6q27; 8p12; 10q11; 11p11
11p12; 11p13; 11p14; 11p15; 13q12; 13q13; 18p11
20q11; 20q12; 20q13
Col 2 colocalizations (APBs) 1p12; 1p13; 1p21; 1p22; 1p31; 1q22; 1q32; 1q41;
1q42; 1q43; 1q44; 2p24; 2p25; 2q31; 2q32; 2q33; 2q34;
2q35; 2q36; 2q37; 3q26; 4p15; 4q35; 8p21; 8p22; 8p23
8q11; 8q23; 8q24; 10q25; 11q13; 12p11; 12p12; 12p13
12q11; 12q13; 12q15; 12q21; 16q22; 16q23; 17p11;17p12
17p13; 20p11; 20q11; 20q12; 20q13
Col 3 colocalizations 1p12; 1p13; 1p21; 1p22; 1p31; 1q22; 1q32; 1q41;
1q42; 1q43; 1q44; 2p24; 2p25; 2q24; 2q31; 2q32; 2q33; 2q34
2q35; 2q36; 2q37; 3q25; 3q26; 3q27; 3q28; 3q29; 4q12;
4q13; 4q21; 4q22; 4q23; 4q24; 4q25; 4q28; 4q31; 6q13;6q14;
6q22; 6q23; 6q24; 8q23; 11p15; 12q11; 12q12; 12q15; 12q21;
12q22; 13q34; 16q12; 16q22; 17p11; 17p12; 17p12; 17p22;
18q11; 20q11; 20q12; 20q13
very large telomeres (VLT) 1p12; 1p13; 1p21; 1p22; 1p31; 1q22; 1q32; 1q41;
1q42; 1q43; 1q44; 2q31; 2q32; 2q33; 2q34; 2q35; 2q36; 2q37;
3q25; 3q26; 3q27; 3q28; 3q29; 5p15; 5q12; 6q12;6q13;6q14;
6q22; 6q23; 6q24; 6q25; 6q26; 8p22; 8p23; 8q23; 9q21;
11p14; 11p15; 11q13; 11q14; 12q11; 12q12; 12q13; 12q14;
12q15; 12q21; 12q22; 16q12; 16q13; 16q22; 17p11; 17p12; 17p12;
20q11; 20q12; 20q13
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telomerase activity (TRAP 2) were 8q22, 8q23 and 8q24 (36%, 39% and 36%), whereas
losses were most frequently found on 11q14; 11q21-q22 (31%). As shown in Figure 2.8,
several chromosome bands signiﬁcantly altered (p < 0.05) in respect to the diﬀerent
telomerase expression levels. Our data revealed, that tumors with moderate telomerase
levels were on several chromosome bands reciprocally altered compared to those tumors
exhibiting a high telomerase expression level (Figure 2.8). For example, chromosome
band 1p12 (p = 0.022) is more often deleted in tumors with high telomerase activity,
whereas the same region is more often gained in tumors with a moderate expression of
telomerase. These chromosomal regions which are reciprocally altered in tumors with
moderate compared to those with high telomerase expression levels (Figure 2.8) are
suggested to play a crucial role in the regulation of telomerase expression.
As shown in Figure 2.9 aﬀected chromosome imbalances (p < 0.05) in tumors ex-
hibiting ALT-mechanism markers, such as Col 1, Col 2, Col 3 and VLT are identically
or similarly altered on several chromosome bands such as 1p12-p13, 1p21, 1q32, 1q44,
2q32-q33 and 20q12-q13 and 1p31, 1q22, 1q41-q43, 2q31, 2q34-q37, 3q26, 16q22, 17p11-
p13 as examples for the markers Col 2, Col 3 and VLT (Figure 2.9). These ﬁndings
indicate that these markers for ALT-mechanism have some properties in common and
seem linked to one another.
As demonstrate in Figure 2.10 tumors detected as ALT positive by Col 1, Col 2, Col 3
and VLT, show on a few chromosome bands (e.g. 1p12, 1p13, 1p21) the same genetic
alteration (p < 0.05) as tumors with moderate telomerase activity, but not with tumors
with high telomerase activity. This indicates that ALT-positive tumors and tumors with
moderate telomerase expression levels share some similar genetic alteration.
Furthermore, we observed that a few chromosome bands show the opposite correla-
tion with respect to tumors with high telomerase expression levels and those exhibiting
markers of ALT (Figure 2.10). Tumors identiﬁed as ALT positive by Col 1, Col 2, Col 3
and VLT showed gains on chromosomes e.g. 1p12-p13 and 1p21, whereas the same
regions were more frequently deleted in tumors with high telomerase activity. Further
opposite alterations observed on chromosome bands among tumors with high telomerase
expression level and ALT-positive tumors are illustrated in Figure 2.10.
2.1.4.5 ALT markers in non-tumor samples
To see, whether the markers of ALT-positive tumors are exclusively expressed in tumor
tissue, we investigated ALT-associated PML-bodies and the heterogeneous size distri-
bution of telomeres (VLT) in non-tumor tissue and normal human ﬁbroblasts cell lines.
For this, we used tissue from skeletal muscle, peripheral nerve, adipose tissue (subcu-
taneous), articular capsule and skin tissue. As shown in Figure 2.11, there is a strong
incidence of APBs in non-tumor tissue and normal ﬁbroblast cells lines. Furthermore,
Figure 2.12 shows that there is no indication that APBs are less or not expressed in
non-tumor samples when compared with soft tissue tumors. With respect to telomere
length distribution, neither the non-tumor tissue nor ﬁbroblast cell lines showed any
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Figure 2.8: Changes on speciﬁc chromosome bands correlates inversely with telomerase ex-
pression levels CGH analyses of all investigated STS revealed several signiﬁcant (p <0.05) alterations
(compare also with 2.1) on diﬀerent chromosomal bands; "Chr.bands"). Data is expressed as a fre-
quency (percentage). -1 demonstrate losses, 0 no alterations and 1 gains (column). Diﬀerent expression
levels are shown in the ﬁrst line. Lines labeled 0, 1 and 2 denote 0 as no, 1 as moderate and 2 as
high telomerase activity. Red (losses) and green (gains) highlight chromosome bands with an higher
frequency. Yellow indicates alteration with the same frequency.
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Figure 2.9: Same genomic alteration in STS in at least three (of the four) markers of ALT
CGH analyses of all investigated STS revealed several signiﬁcant (p<0.05) alteration (compare also
with 2.1 on diﬀerent chromosomal bands (Chr.bands). Data expressed as frequency (percentage). -1
demonstrate losses, 0 no alterations and 1 gains (collum). Markers for ALT are show in the ﬁrst line:
Col1 labeled with 0, 1 and >1 denotes none (0), one (1) and more than one (>1) colocalization per
sample; Col2, Col3 and VLT (verly large telomeres): denotation by 0, 1-3 and > 3 indicate non (0), 1
to 3 (1-3) and more than 3 (>3) colocalization or VLT spot per sample. Red (losses) and green (gains)
indicate chromosome bands with an higher frequency. Yellow demonstrate alteration with the same
frequency.
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Figure 2.10: Diﬀerent expression level of telomerase show invers alteration revealed to the
same chromosome bands CGH analyses of all investigated STS revealed several signiﬁcant (p<0.05)
alteration (compare also with 2.1 on diﬀerent chromosomal bands (Chr.bands). Data expressed as fre-
quency (percentage). -1 demonstrate losses, 0 no alterations and 1 gains (collum). Diﬀerent expression
level are shown in the ﬁrst line: lines labeled with 0, 1 and 2 denotes for 0 = no, 1 = moderate and 2
= high telomerase activity. Red (losses) and green (gains) indicate chromosome bands with an higher
frequency. Yellow demonstrate alteration with the same frequency.
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Figure 2.11: ALT-associated PML bodies in non-tumor samples. APBs and heterogeneous
telomere spot size distribution were detected by combined telomere ﬂuorescence in situ hybridization
and PML immunoﬂuorescence in frozen section of non-tumor samples and ﬁbroblast cell lines. (A)
Normal human skin-sections and (B) normal human ﬁbroblasts showing the incidences of APBs. Ar-
rows indicate APBs (telomere staining in red, PML staining in green) as well as enlarged picture (see
cutout). No heterogeneous size distributions of telomeres were observed; neither in the samples of normal
ﬁbroblast cell lines nor in the non-tumor sections. Nuclei were counterstained with 4',6-diamidino-2-
phenylindol (blue). Using confocal laser scanning microscopy, 3D images were acquired from at least
three independent regions of the investigated specimens.
large telomere spots (Figure 2.12). This analyses shows that APBs as marker for ALT
are independently found in both, non-tumor samples and tumors samples, whereas very
large telomeres are exclusively detected in the investigated tumor specimens.
2.1.5 Discussion
Telomere length regulation, on the one hand, can provide a tumor suppressor function by
limiting replicative potential, and on the other hand, allow tumor cells to proliferate in-
deﬁnitely due to the activation of a telomere maintenance mechanism. Consequently, the
establishment of a TMM has received greater attention as a target for new chemother-
apeutic strategies. We focused our study on the frequency distribution of telomere
maintenance mechanisms in diﬀerent subtypes of soft tissue sarcomas. A better charac-
terization of telomere maintenance mechanisms would facilitate a more tightly focused
development and testing of telomerase as a therapeutic target and might initiate the
development of a target-oriented therapy against tumors that exhibit ALT mechanism.
It is suggested that mesenchymal tissue have a slower cell turnover and less telomere
shortening than epithelia, which may lead to a stronger repression of telomerase activity.
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Figure 2.12: ALT-associated PML bodies in non-tumor samples and soft tissue tumors.
Comparison of ALT markers in soft tissue sarcoma and non-tumor samples. There is a strong incidence
of a similar level of APBs in non-tumor samples (red) and normal human ﬁbroblasts (blue) compared
to those tumors of the soft tissue (green). Nevertheless, no heterogeneous size distributions of telomeres
were observed in non-tumor section or in normal human ﬁbroblast cell lines. Colocalizations (APBs)
labeled Col 1 with 0, 1 and >1 denotes none (0), one (1) and more than one (>1) colocalization per
sample respectively; Col 2, Col 3 and VLT (very large telomeres) are subdivided into 0, 1-3 and >3: to
indicate none (0), 1 to 3 (1-3) and more than 3 (>3) colocalizations of Col 2, Col 3 or VLT spot per
sample.
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The activation of ALT is more likely to occur in sarcomas than in carcinomas (Henson
et al. 2002).
We analyzed the frequency of telomerase expression levels (low, moderate and high)
in diﬀerent subtypes of soft tissue sarcomas, such as leiomyosarcomas (LMS), malig-
nant peripheral nerve sheath tumors (MPNST), malignant ﬁbrous histiocytoma (MFH),
synovial sarcomas (SS), pleomorphic liposarcomas (PLLS), myxoid round cell liposar-
coma (MRCLS) and dediﬀerentiated liposarcoma (DDLS). Our data revealed that each
subgroup of soft tissue sarcomas has a diﬀerent signature in the expression level of
telomerase. This could lead to a diﬀerent eﬃcient response to therapies that would
target telomerase. Tumor samples with speciﬁc translocations such as MRCL (myxoid
round cell liposarcomas) and SS (synovial sarcomas) show an up-regulated telomerase
activity compared to those tumors with non-speciﬁc translocations, like pleomorphic
and dediﬀerentiated liposarcoma. These data suggest that soft tissue sarcomas with a
speciﬁc translocation, are more prone to expressing telomerase unlike tumors with more
complex karyotypes.
In order to determine the prevalence of the ALT mechanism, we detected markers
for ALT such as ALT-associated PML-bodies (APBs) and heterogeneous size distribu-
tion of telomere signals, with exceptionally long telomeres and correlated these data
with the diﬀerent expression levels of telomerase. Our study shows for the ﬁrst time
an inverse correlation between telomerase expression levels and markers for ALT. High
telomerase expression level correlates with a decreased number of APBs and very large
telomeres (VLT). We only occasionally detected a large amount of huge telomere spots
in tumors with a high level of telomerase expression. Only two cases, one in MFH and
the other in MPNST, displayed large telomere signals, despite having a high telomerase
expression level. This could explain why carcinomas, which usually maintain telomere
length by the reactivation of telomerase, show telomere, which are equal in length with-
out exceptionally long telomeres. These data are also consistent with further studies
that showed in vitro that ALT is suppressed upon fusion of ALT positive cell lines with
telomerase-positive cell lines (Perrem et al. 1999).
In our study we observed, that APBs as well as VLT, are increased in tumors with
moderate telomerase activity compared to those tumors without telomerase activity. The
data indicate that both mechanisms can exist in the same tumor but preferentially, when
tumors express a moderate telomerase expression level in alignment with other studies
(Johnson and Broccoli 2007). We cannot conclude whether in these cases telomerase is
slightly repressed by the induction of APBs and VLT, or whether, for some other reason,
these tumors are up-regulating telomerase to a low level, allowing, in turn, an increased
number of APBs and VLT. The mechanism of telomerase reactivation remains unknown,
but epigenetic mechanism are suggested to be involved in the regulation of telomerase
expression (Atkinson et al. 2005), and could partially explain why some tumors express
high telomerase activity whereas others are more prone to the ALT pathway. While our
data show that both mechanisms can be detected in the same tumor sample, it is not yet
known whether both mechanisms function in the same cells, diﬀerent cells, or in speciﬁc
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regions of the same tumor.
Investigation of non-tumor samples and normal human ﬁbroblasts showed the presence
of APBs in similar form and quality, whereas, in contrast heterogenous size distribution
and very large telomeres were exclusively detected in tumor samples. Based on the
observation that ALT-associated PML bodies (APBs) contain telomeric DNA and pro-
teins, which are involved in DNA repair and recombination, one can agree that APBs
play an important role in the ALT mechanism (Yeager et al. 1999; Johnson et al. 2001).
Studies by, Kumar et al. (2007) showed that PML NB and SATB1 regulate chromatin-
loop architecture like t-loops (telomeric loops). The latter are accomplished by proteins
such as Mre11, NBS1 and RAD50. Based on this ﬁnding, it is possible that not only
recombination-based proteins are involved in t-loop conformation, but also in PML,
which might then lead to the formation of APBs. Recent studies by Jiang et al. (2009)
showed that APBs are also induced in growth-arrested senescent cells. From our data
we cannot conclude whether the presence of APBs in non-tumor samples is also induced
by the ALT-mechanism or by another mechanism besides of ALT. Further studies will
need to be done to address this issue and clarify how tightly these nuclear structures are
linked to ALT mechanism and whether APBs can still be used as markers for the detec-
tion of ALT-like tumors. Altogether, the data suggest that very large telomeres (VLT)
signals have a stronger association with the ALT-mechanism than ALT-associated PML
bodies.
A previous study by Johnson et al. (2007) revealed that ALT positive tumors have on
average, a higher level of genomic instability than tumors without incidences of ALT or
compared with tumors exhibiting telomerase activity. To investigate whether telomere
maintenance mechanisms correlate with genomic instability, we performed comparative
genomic hybridization (CGH). Our data revealed that the occurrence of a TMM did
not inﬂuence the amount of genomic aberration i.e. copy number of chromosome bands.
Except for Col 2 colocalization as a marker for ALT has shown signiﬁcant more am-
pliﬁcation with an increased number of these colocalizations. These ﬁndings are not
entirely consistent with the work of Johnson et al. (2007) and Scheel et al. (2001). The
group of Johnson et al. (2007) investigated by whole-genome proﬁling of liposarcomas
and found in ALT positive tumors, a higher level of genomic instability. The latter
group analyzed osteosarcoma-derived cell lines that utilized either ALT or telomerase,
by using both telomere and multiplex in situ hybridization (FISH). The data revealed an
increased number of translocation, deletion and complex rearrangements in ALT-positive
cell lines compared to those with telomerase activity.
The work of Montgomery et al. (2004) also proposed that there is a correlation be-
tween very large telomeres and pleomorphic sarcomas that typically possess complex
karyotypes. Consistent with the present study, pleomorphic liposarcomas showed a high
percentage (92%) of very large telomere signals, whereas 54% of these tumors lacked any
detectable telomerase activity. In strong contrast, synovial sarcoma and myxoid round
cell liposarcoma, both comprising to sarcomas with speciﬁc translocations, showed no ev-
idence for heterogeneous telomere length distribution. APBs were found independently
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in both soft tissue sarcomas subtypes translocation-associated and with complex kary-
otype. It is known that the speciﬁc spatial arrangements in normal cells are important
for the generation of chromosomal translocation. Consequently the organization of the
human genome seems to be crucial in the generation of translocation-associated malig-
nancies (Zink et al. 2004). It is possible, that the spatial rearrangement of the human
genome is organized diﬀerently in cells that show telomeres, which are equal in size and
those tumors which have exceptionally long telomeres. Nevertheless, it is not yet known,
which mechanism is responsible for translocation-associated sarcomas being more likely
to exhibit telomerase activity, than sarcomas with complex karyotypes, which tend to
lack high telomerase expression levels. It is also not known why, on the contrary, tumors
with complex karyotypes show an increased number of very large telomeres, whereas
sarcomas of simple karyotypes do not possess telomeres, which are exceptionally long.
Further studies with a higher number of translocation-associated tumors and tumors
with komplex karyotypes will need to be done to address this issue and clarify this
observation.
The detection of frequently over- or underrepresented chromosomal regions and the
comparison to markers of telomere maintenance mechanisms by comparative genomic
hybridization (CGH) suggests the presence of genomic regions being involved in the reg-
ulation of telomere maintenance mechanisms. We investigated very diﬀerent subgroups
of soft tissue sarcoma with respect to genetic alterations, CGH analyses revealed that
tumors with high telomerase activity share some common imbalances. The same obser-
vations were found for markers of ALT, which suggests that these markers are linked to
one another. Furthermore, several loci with respect to the diﬀerent TMMs turned out to
be inversely altered. Investigations of these regions might encode genes, which are linked
to both or either telomere maintenance mechanism. The observation that tumors with
moderate telomerase activity share some of the same alterations with the ALT mark-
ers, which are inversely altered compared to those tumors with high telomerase activity,
suggests that genes in these region are involved in the up-regulation of high telomerase
expression level. Furthermore, these data suggest that tumors with high telomerase
expression level and tumors with moderate telomerase activity are genetically diﬀerent.
The chromosomal region 17p11-p12 was frequently gained in tumors possessing ALT,
detected by the markers Col 2, Col 3 and VLT. These chromosome bands are of great
interest, as they contain three homologous sequences which are known to be involved in
recombination processes, resulting in duplications and deletions (Chen et al. 1997).
Tumors exhibiting abundant amounts of Col 2, Col 3 and VLT are frequently gained
(40%, 50%, 43% respectively) on chromosome 17p13, where the tumor suppressor gene
TP53 is located. These ﬁndings are in contrast with other studies that proposed that
the interference of TP53 might create a more amenable environment for ALT (Johnson
et al. 2007) as the loss of p53 increases homologous recombination (Henson et al. 2002).
Further studies in ALT positive tumors that address the expression of p53 may explain
the association of the p53 protein expression level with the ALT mechanism.
Deletion in tumors with markers for ALT (Col 2, Col 3, VLT) have been frequently
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found on chromosome region 16q22. This may be of interest, as TRF2, one of the
shelterin-proteins, is localized and is known to play an important role in preventing
telomeres from being recognized as sites of DNA damage in order to avoid checkpoint
activation and inappropriate DNA-repair (Denchi 2009).
In summary, our data indicate that telomerase expression levels is associated with the
subtype of soft tissue sarcomas. Investigating the diﬀerent telomerase expression level
showed that tumors with high telomerase expression levels and those with moderate
expression level are on some chromosome bands inversely altered. The genomic regions
of this inverse alteration might be involved in the up-regulation of either high or moderate
to no telomerase activity. This could have an implication in the response to therapies
with telomerase inhibition as the aim. In addition, investigations of non-tumor samples
showed that very large telomeres are more tightly associated with the ALT- mechanism
than APBs. Further investigation of APBs in non-tumor samples could clarify if these
markers are induced by the ALT mechanism or by some other mechanism besides ALT.
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2.2.1 Abstract
We introduce a new model-based approach for automatic quantiﬁcation of colocaliza-
tions in multi-channel 3D microscopy images. The approach is based on diﬀerent 3D
parametric intensity models in conjunction with a model ﬁtting scheme to localize and
quantify subcellular structures with high accuracy. The central idea is to determine
colocalizations between diﬀerent channels based on the estimated geometry (position
and shape) of subcellular structures as well as to diﬀerentiate between diﬀerent types of
colocalizations. Furthermore, we perform a statistical analysis to assess the signiﬁcance
of the determined colocalizations. We have successfully applied our approach to about
400 three-channel 3D microscopy images of human soft-tissue tumors
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2.2.2 Introduction
Human telomeres are the physical ends of linear chromosomes that protect them from
improper DNA metabolism. Telomere shortening, due to the incomplete synthesis of
linear DNA during replication, plays an important role aging and cancer. The activa-
tion of a telomere length maintenance mechanism (TMM) is thus essential for cellular
immortalization and long-term tumor growth. Telomerase activity is the most common
TMM, particularly in tumors of epithelial origin. However, some tumors, among them
speciﬁc subtypes of soft tissue sarcomas, have been shown to maintain telomere length
by a recombination-based mechanisms that have been termed alternative lengthening
of telomeres (ALT) (Montgomery et al. 2004). Since the telomere length maintenance
mechanisms (TMM) can vary signiﬁcantly in soft tissue sarcomas, its characterization
is crucial for developing new strategies for therapies.
Promyelocytic leukemia (PML) bodies are subnuclear entities colocalizing with various
proteins in the cell nucleus. A preferential colocalization of PML bodies with telomeres
is indicative for the ALT mechanism (Fasching et al. 2007). A further indication of ALT
is their highly heterogeneous telomere lengths with some exceptionally long telomeres
(Fasching et al. 2007).
The aim of this study is to assess ALT in human soft tissue sarcomas by combined
telomere ﬂuorescence in situ hybridization and PML immunoﬂuorescence. Using a con-
focal laser scanning microscope, we acquired about 400 three-channel 3D ﬂuorescent
microscopy images of soft-tissue sarcomas, which visualize telomere spots in the ﬁrst
channel, PML bodies in the second channel, and DAPI-stained nuclei in the third chan-
nel (e.g., see Figure 2.13 for maxima intensity projections of a typical example). The
central task of image analysis is to automatically detect and classify colocalizations of
telomeres and PML bodies within the cell nucleus as well as to automatically detect and
quantify very large telomere signals.
In previous work on quantifying the ALT mechanism, colocalizations were often esti-
mated manually or semi-automatically, which is subjective, error prone, and time con-
suming (e.g., Fasching et al. (2007)). Automatic approaches for colocalization analysis
can be classiﬁed into intensity-correlation-based and object-based schemes (see Bolte
and Cordelières (2006) for a review). With intensity-correlation-based schemes, global
colocalization measures are computed, which directly correlate the intensity information
of two channels (e.g., Manders et al. (1993); Comeau et al. (2006)). Main disadvan-
tages are the sensitivity w.r.t. image contrast and noise as well as the global nature
of the schemes, i.e., the number of colocalizations cannot be quantiﬁed. In contrast,
with object-based schemes a segmentation of the relevant image structures is obtained,
which is used to determine colocalizations between two channels (e.g., Fay et al. (1997);
Lachmanovich et al. (2003); Zhang et al. (2008)). However, so far typically spot-like
structures have been considered using, for example, a threshold-based scheme (Fay et al.
1997), a watershed transform (Lachmanovich et al. 2003), or a wavelet transform (Zhang
et al. 2008). Moreover, these approaches only consider distances between spots to deter-
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Figure 2.13: Maxima intensity projections of a three-channel 3D microscopy image of a
soft tissue tumor and enlarged section a) telomere channel, b) PML channel, c) DAPI- channel,
d) enlarged section of telomere spots (framed in picture a).
mine colocalizations (Fay et al. 1997; Zhang et al. 2008) or have only been applied to 2D
images (Lachmanovich et al. 2003).
In this contribution, we introduce a new model-based approach for automatic quantiﬁ-
cation of colocalizations and very large telomere signals in multi-channel 3D microscopy
images. Our approach is based on 3D parametric intensity models in conjunction with a
model ﬁtting scheme to localize and quantify telomeres and PML bodies with high accu-
racy. 3D intensity models have been previously used to segment subcellular structures
(e.g., Thomann et al. (2002); Heinzer et al. (2008)). However, so far these approaches
only used 3D Gaussian models and they have not been used for the detection of colocal-
izations. The central idea of our approach is to determine colocalizations of subcellular
structures between diﬀerent channels based on the estimated geometry (position and
shape), which is estimated with subvoxel resolution using a combination of diﬀerent
3D intensity models. In contrast to previous colocalization approaches (e.g., Fay et al.
(1997); Lachmanovich et al. (2003); Zhang et al. (2008)), our approach not only allows
to accurately detect colocalizations but also to diﬀerentiate between diﬀerent types of
colocalizations. Furthermore, we perform a statistical analysis to assess the signiﬁcance
of the determined colocalizations. In contrast to previous approaches, which analyze
manually chosen regions in diﬀerent areas of both channels (Lachmanovich et al. 2003)
or which test the distribution of individual spot distances based on a manual segmenta-
tion of the cell area Zhang et al. (2008), we introduce a fully automatic 3D scheme for
assessing the signiﬁcance of the determined colocalizations.
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2.2.3 Quantiﬁcation of colocalizations
In the following, we describe our new model-based approach for the analysis of 3D
microscopy images. The approach comprises i) the detection and quantiﬁcation of sub-
cellular structures and cell nuclei in three diﬀerent channels, ii) the detection and clas-
siﬁcation of colocalizations between the segmented subcellular structures, as well as iii)
an analysis of the statistical signiﬁcance of the detected colocalizations.
2.2.3.1 3D Model-Based Segmentation
Telomeres and PML bodies appear as a larger number of bright spots on a diﬀuse
background where both the size and contrast of the spots varies (see Figure 2.13). To
segment these structures, we propose a two-step approach. In the ﬁrst step, we apply
diﬀerent image analysis operations to the 3D images to obtain coarse center positions
of the diﬀerent spots. These operations include Gaussian smoothing for noise reduction,
image clipping with automatically estimated threshold value for background suppression,
and local maxima search for spot detection (see Heinzer et al. (2008) for details).
In the second step, we quantify each detected spot candidate from the ﬁrst step based
on least-squares model ﬁtting. For PML bodies as well as for small and medium sized
telomeres, which account for most of the telomeres, the 3D intensity proﬁle can be well
represented by a 3D Gaussian function
gGaussian3D(x) = exp
(
− x
2
2σ2x
− y
2
2σ2y
− z
2
2σ2z
)
(2.1)
where x= (x, y, z) and (σx, σy, σz) are the standard deviations of the Gaussian. By
including intensity levels a0 (background) and a1 (spot) as well as a 3D rigid transform
R with rotation parameters α=(α, β, γ) and translation parameters x0=(x0, y0, z0), we
obtain the 3D parametric intensity model
gM(x,p) = a0 + (a1 − a0) gGaussian3D(R(x)) (2.2)
where p represents the overall parameter vector of the model. To ﬁt the model to the im-
age data, we use the non-linear least-squares optimization scheme of Levenberg/Marquardt.
As a result, we obtain for each spot estimates of all model parameters. Note that the
estimated parameter values are real numbers, i.e., our approach determines, for example,
subvoxel positions of the spots as well as subvoxel estimates of the standard deviations
which determine the spot size.
However, for very large telomere signals (cf. the center spot in Figure 2.13, d)) the
3D intensity proﬁle signiﬁcantly deviates from a Gaussian shape. We propose to model
these telomeres using a 3D superellipsoidal model, which previously has been used to
segment bacteria (Wörz et al.) but not to segment subcellular structures. Using the
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Figure 2.14: Colocalization types c1 to c5
Figure 2.15: Colocalization types c1 to c5 as well as segmentation results Segmentation results
for the framed region shown in Figure 2.13 a) telomeres, b) PML NBs, c) identiﬁed colocalizations.
Gaussian error function Φ(x)=
∫ x
−∞ (2pi)
−1/2 e−ξ
2/2 dξ, this intensity model is given by
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where σ is the standard deviation of Gaussian image blur, (rx, ry, rz) are the semi-axes
of the superellipsoid, and  describes its roundness (e.g.,  = 2 is an ellipsoid and →∞
yields a cuboid). By including intensity parameters and a 3D rigid transform, the 3D
parametric intensity model is obtained analogously to (2.2). To segment the telomere
channel, we propose a two-pass approach. In the ﬁrst pass, the above described two-step
approach with an adaptation to large spots is applied, e.g., using the superellipsoidal
model, which is initialized based on the ﬁtting results of the Gaussian model. In the
second pass, the smaller spots are segmented using the two-step approach where the
regions of the large spots are masked to prevent false spot candidates at the boundary
of large spots. To segment the DAPI-stained cell nuclei in the third channel, we apply
3D median and Gaussian ﬁlters for noise reduction with subsequent Otsu thresholding.
As a result, we obtain a binary segmentation of the cell nuclei.
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2.2.3.2 3D Colocalization Quantiﬁcation
To determine colocalizations between subcellular structures of diﬀerent channels, we
propose the following scheme. The central idea is to utilize the quantiﬁed geometry
of the structures based on the ﬁtting results of the parametric intensity models, i.e.,
the 3D position, 3D orientation, and 3D shape (speciﬁed by the standard deviations
and semi-axes of the Gaussian and superellipsoidal model, respectively). We deﬁne a
colocalization as an (partial) overlap of two (or more) structures from diﬀerent channels.
Since, in contrast to previous approaches (e.g., Fay et al. (1997); Lachmanovich et al.
(2003); Zhang et al. (2008)), we obtain a geometric representation of the structures with
subvoxel resolution, we are able to diﬀerentiate between diﬀerent types of colocalizations.
In this application, we use in total six diﬀerent types. The types c1 to c5 (see Fig-
ure 2.14) represent colocalizations between PML bodies (grey) and small/medium sized
telomeres (black): c1 (c2) is a colocalization where a telomere (PML body) is fully within
a PML body (telomere), in a c3 colocalization both spots overlap and the center of each
spot is within the other spot, and c4 (c5) is a colocalization where a smaller telomere
(PML body) partly overlaps with a larger PML body (telomere). In addition, c6 denotes
a colocalization of a PML body with a very large telomere signal, which is quantiﬁed
using the superellipsoidal model. Furthermore, in our application also multiple colocal-
izations occur, for example, a colocalization of one PML body with two telomeres. Here
we add these cases to the respective types c1 to c6 and do not consider them as diﬀerent
types. Overall, we count the number nci of colocalizations of each type ci, the total
number nc summed over all types, as well as the number of colocalized telomeres (nctel)
and PML bodies (ncpml), which can deviate from nc due to multiple colocalizations.
2.2.3.3 Analysis of the Signiﬁcance of Colocalizations
To assess the signiﬁcance of the estimated number of colocalizations, we perform an
automatic statistical analysis given the null hypothesis that the observed colocalizations
are a result of a random distribution of the spots. This analysis is based on repeated
random distributions of the segmented telomeres and PML bodies within the segmented
volume of the DAPI channel. For each random distribution, the number of colocaliza-
tions (nc1 , . . . , nc6 , nc, nctel , ncpml)j is determined as described above. For all r random
distributions, Σ is the number of distributions that yield a number of colocalizations
greater than or equal to the experimental result. The empirical p-value is given by
p = Σ/r, which can be compared to a certain level of signiﬁcance α. Since we ﬁnally
apply our approach to a large number of n ≈ 500 images, we use a Bonferroni correc-
tion: given the experiment-wide false positive value pi, the applied level of signiﬁcance
is α = pi/n. Here, we chose r = 100, 000 random distributions and a value of pi = 0.05,
which yields α = 0.0001. Thus, we can state for each type of colocalization in each image
if the number of detected colocalizations is signiﬁcant (i.e., reject the null hypothesis)
or not.
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ntel npml nc nc1 nc2 nc3 nc4 nc5 nc6
Image 1 458+8 231 89 3 (1) 34 29 16 6
Image 2 479+5 181 22 (0) (0) (3) (11) (1) 7
Image 3 742+1 331 (16) (0) (0) (0) (16) (0) (0)
Table 2.2: Number ntel of segmented telomeres (normal + very large), number npml of PML bodies,
total number nc of colocalizations, as well as the numbers nc1 , . . . , nc6 of diﬀerent types of colocalizations
for three images. Colocalization results which are not signiﬁcant are put in parenthesis.
2.2.4 Experimental results
We have applied our approach to about 400 three-channel 3D ﬂuorescent microscopy
images of human soft-tissue tumors. The images have a size of about 512 × 512 × 25
voxels. For all images, we used the same parameter settings. Overall, we achieved
quite good segmentation results. For example, Figure 2.15 shows a maxima intensity
projection of the segmentation results for the region marked in Figure 2.13. Shown are
the center positions of the segmented telomeres and PML bodies as well as the detected
colocalizations together with their type.
For the image shown in Figure 2.13 (image 1) as well as for two additional images,
Table 2.2 exemplarily shows the number ntel of segmented telomeres (normal + very
large), the number npml of PML bodies, the total number nc of colocalizations, as well
as the numbers nc1 , . . . , nc6 of diﬀerent types of colocalizations. Colocalization results
which are not signiﬁcant are put in parenthesis. It can be seen that the number of colo-
calizations as well as the signiﬁcance of these colocalizations is very diﬀerent in all three
images. Interestingly, whereas the number of segmented telomeres and PML bodies in
the ﬁrst two images is similar, the total number of colocalizations nc diﬀers by a factor
of 4. Still, the total number of colocalizations nc = 22 of image 2 is signiﬁcant. Con-
sidering individual types of colocalizations, it can be seen that the level of signiﬁcance
varies between diﬀerent types. For example, in image 2 a number of nc4 = 11 colocaliza-
tions is not signiﬁcant, whereas a number of nc6 = 7 colocalizations is signiﬁcant. As a
consequence, the statistical analysis of the signiﬁcance of the number of colocalizations
is important to allow an accurate analysis of the colocalization results. Interestingly,
the total number nc = 22 of colocalizations of image 2 is signiﬁcant even though the
types c1 to c5 are not signiﬁcant. The reason is that the type c6 is signiﬁcant: there
are nc6 = 7 (multiple) colocalizations with the 5 very large telomere signals (only two
random distributions yielded nc6 = 7, the mean is 0.563).
The computation time for a single three-channel 3D image mainly depends on the
number of telomeres and PML bodies, and is about 1-2min for 3D segmentation and
colocalization detection (on an AMD Opteron PC with 2.6GHz).
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2.2.5 Discussion
We introduced a new model-based approach for automatic quantiﬁcation of colocaliza-
tions and very large telomere signals in multi-channel 3D microscopy images. The ap-
proach is based on 3D parametric intensity models in conjunction with a model ﬁtting
scheme to localize and quantify telomeres and PML bodies with high accuracy. The
central idea of our approach is to determine colocalizations based on the estimated ge-
ometry (position and shape) of subcellular structures as well as to diﬀerentiate between
diﬀerent types of colocalizations. Furthermore, we performed a statistical analysis to as-
sess the signiﬁcance of the determined colocalizations. We have successfully applied our
approach to about 400 three-channel 3D ﬂuorescent microscopy images of human soft-
tissue tumors. Current and future work are the detailed analysis of the colocalization
results w.r.t. biological meaning.
2.2.6 Veriﬁcation of the automated spot detection by a manual
analysis (unpublished data)
In order to verify the results of the automated spot detection, we performed a manual
analysis of a set of ﬁve 3D images with respect to diﬀerent investigators. The images were
segmented twice with an intermission of 4 weeks by investigator 1, once by investigator
2 (Petra Sander), and once by investigator 3. The manual analysis was performed
in two steps. First, telomere spots and PML spots were selected with the programm
PointEdit3D shown in Figure 2.16, provided by Dr. Peter Matula (German Cancer
Research Center, Dept. Bioinformatics and Functional Genomics). In a second step,
selected spots were imported into ImageJ with a plug-in created by Martin Pfannmöller
(CellNetworks - Cluster of Excellence, Heidelberg University). With the assistance of
this plug-in, previously picked spots were depicted and used to highlight the spots in the
original programm ImageJ. This was further used to determine manual colocalization
between the two channels of telomeres and PML. In additional original z-stacks were
then consulted to determine the type of colocalization according to the criteria shown
in chapter 2.2.
2.2.6.1 Results
The manual spot detection was performed using the PointEdit3D application to mark
the spots in 3D confocal images. The analysis was done by diﬀerent experimenters (1-3)
in order to assess whether outside factors and personal preferences inﬂuence the anal-
ysis results. Interestingly enough, investigator 1 (Tabea) counted 3-20% less telomeres
(except for test image 4) and 10-75% less PML bodies 4 weeks after her ﬁrst analysis
of the same images. In additional investigator 2 (Petra Sander) counted consistently
lower numbers for telomeres and PML bodies than investigator 1 (Tabea). In summary,
the results show no consistency between the three sets of results. Furthermore, a high
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Figure 2.16: Manual analysis of 3D images by the program PointEdit3D To verify the auto-
mated spot detection a manual analysis was performed assisted by the program PointEdit3D. For the
spot detection (by 4 diﬀerent investigator) a x-z-plane (bottom frame) was used. The other two views
were used to verify the selected spots
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Figure 2.17: Results of manual spot detection by diﬀerent investigators a) Manual detection
of telomeres (a) and manual detection of PML (b) bodies of 5 diﬀerent test images (using 3D confocal
microscopy) First results from investigator 1 (Tabea) are shown in blue and her second results after
5 weeks are shown in orange, results form investigator 2 (Petra Sander) are shown in yellow. Exact
number of counted spots are shown within the bar graphs. (Data provided by Stefan Wörz)
instability in the number of spots occurs for almost all images between the diﬀerent
investigators. Results are illustrated in Figure 2.17 and 2.19. Same results are observed
for the manual detection of colocalization by the diﬀerent experimenters. Data shown
in Figure 2.18
For the automatic analysis, diﬀerent parameters for the program CellSegmentation
were chosen in order to ﬁnd a standard set to analyze the images optimally, regardless of
their quality. Using the chosen parameters the ﬁve test images that had been analyzed
manually were evaluated by the program. The results, shown in Figure 2.20, indicate
that the automated detected signals fall into the range of the manual results for almost
all images. Some images were re-evaluated using a diﬀerent set of parameters for the
program CellSegmentation. These results are more similar to the results obtained man-
ually. Finally the parameters chosen to evaluate more than 400 3D images by confocal
microscopy have been done by Petra Sander. Therefore automated detected spots in
71
2 Publications - in preparation and submitted - based on this thesis
Figure 2.18: Results of manual colocalization detection by diﬀerent investigators a) Manual
detection colocalization of 5 diﬀerent test images (using 3D confocal microscopy) Manual analysis are
shown in blue with error bars. Error bars showing highest and lowest values of the diﬀerent manual
analysis. Results from automated analysis with standard parameters are illustrated in orange. In
yellow are re-analyzed automated colocalization with changed parameters. Exact numbers of detected
colocalizations are shown within the bar graphs.(Data provided by Stefan Wörz)
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Figure 2.19: Manual spot detection of 3 diﬀerent investigators The manual analysis of telomeres
and PML bodies by three diﬀerent experimenters (Tabea, Petra Sander and Kolja) shows obviously a
strong variety of the counted spots in both channels. (Data provided by Stefan Wörz)
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Figure 2.20: Comparison of manual and automated spot detection of 3D confocal mi-
croscopy images a) detected telomere spots b) detected PML spots. Manual analysis illustrate in
blue, error bars showing the highest and lowest counted spots of the diﬀerent experimenters. Results of
the automated spot detection are shown in orange. Re-analyzed automated spot detection with changed
parameters are shown in yellow. Raw data of counted spots are shown within the bar graphs. (Data
provided by Stefan Wörz)
about 100 3D images of soft tissue sarcoma were proven and for the parameters of the
CellSegmentation program adapted (Data not shown). These sets of parameters were
ﬁnally used for the screening of tumor samples and non-tumor samples to investigate
the ALT-mechanism.
Most work on quantifying the ALT mechanism, and colocalization was measured man-
ually or semi-automatically. The results of these small experiments show that the manual
spot detection and colocalization analysis strongly varies among diﬀerent experiments.
Consequently, manually estimations are not only time consuming but also subjective
and error prone.
74
3 Unpublished additional experiments
3.1 ALT-associated PML bodies: Does any
PML-isoform colocalize preferential with
telomeres?
3.1.1 Abstract
Cancer cells are able to prevent telomere shortening by activating a telomere mainte-
nance mechanism. Most immortalized cells and cancer cells apply a telomerase-dependent
mechanism for telomere maintenance. Some tumors maintain telomere length by a re-
combination based mechanism that has been termed alternative lengthening of telomeres
(ALT). Promyelocytic leukemia (PML) has been implicated in a variety of functions,
including a preferential colocalization of PML bodies with telomeres, also referred as
ALT-associated PML bodies (APBs) and are indicative for the ALT mechanism. The
aim of this study was to investigate the PML protein isoforms in cell lines with diﬀerent
mechanisms of telomere maintenance. For our analyses the cell lines HeLa and MCF7
(Telomerase positive), U2OS (ALT positive) and VH7 (without telomere maintenance
mechanism) were used. The protein level of the individual PML isoforms were investi-
gated by Western-blot analysis of whole-cell extracts and nuclear fraction from whole cell
extracts and found diﬀerent bands representing diﬀerent spliced PML isoforms. With
respect to the cell lines exhibiting diﬀerent telomere maintenance mechanisms, the re-
sults showed no signiﬁcant diﬀerences in the protein-level of the speciﬁc PML isoforms.
In order to show to which extent any PML protein isoform colocalizes preferentially
to telomeres, the diﬀerent PML isoforms were investigated. Six GFP-tagged PML iso-
forms (located in the nucleus) were transiently transfected into U2OS (ALT positive) cell
lines, MCF7 and Hela cell lines, both telomerase positive. From our results, we cannot
conclude that any PML splice variants preferentially colocalize with telomeres. These
ﬁndings suggest that a knock down of PML protein isoforms might be a better approach
to investigate the role of individual PML isoforms and their role in APBs assembling
and therefore in the alternative pathway of telomere maintenance.
3.1.2 Introduction
Most immortalized human cells, as well as most cancer cells, maintain their telomeres
by activating a telomere maintenance mechanism, either by telomerase (Greider and
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Blackburn 1985), or by alternative lengthening of telomeres (ALT) (Bryan et al. 1995).
One indication of ALT is their highly heterogenous telomere lengths with some excep-
tionally long telomeres (Fasching et al. 2007). Another hallmark is the colocalization
promyelocytic leukemia (PML) bodies with speciﬁc proteins such as TRF1 and TRF2,
and telomeres.
PML is expressed in all mammalian tissue and cell lines (Gambacorta et al. 1996).
The typical number of PML nuclear bodies (PML NB) in mammalian cells is 1 to 30
per nucleus, depending on cell cycle phase, diﬀerentiation stage and cell type. PML
nuclear foci are between 0.2 and 1.0 µm wide. Many proteins localize permanently or
transiently to PML nuclear bodies. As a consequence, PML bodies have been implicated
in the regulation of diﬀerent cellular function such as the induction of apoptosis, inhibi-
tion of proliferation, induction of cellular senescence, maintenance of genomic stability
and antiviral responses. Further, cellular processes, in which PML NB might be involved,
are modulation of chromatin structures, transcriptional regulation of speciﬁc genes, pro-
tein sequestration and posttranslational modiﬁcation of target proteins (Bernardi and
Pandolﬁ 2007).
The characteristic protein of PML NBs is the promyelocytic leukemia gene product
PML. The human gene PML was identiﬁed as the fusion partner of the gene RARA
(retinoic acid receptor alpha) in the chromosomal translocation t(15:17) in acute promye-
locytic leukemia (APL) (de Thé et al. 1991). PML is composed of nine exons of which
exon 5-9 can be alternatively spiced, resulting in speciﬁc isoforms (Jensen et al. 2001).
Exon 1 to 3 encodes the TRIM motif (RBBC, Ring ﬁnger, B-box, coiled-coil) and is
present in all PML isoforms. PML harbors three SUMOylation sites, and SUMOyla-
tion of PML is essential for PML nuclear body assembly (Zhong et al. 2000a). Further
motifs have been identiﬁed in the C-terminus of PML and all PML isoforms, such as
the nuclear localization signal (NLS) and a SUMO-interacting motif (Henderson and
Eleftheriou 2000).
In this study, we ﬁrst analyzed the composition and functions of the PML protein
isoforms in cell lines, showing diﬀerent telomere maintenance mechanisms. Isoform pro-
tein expression patterns were detected by Western blot analysis. Further we established
a combination of GFP-tagged PML isoforms transfection with ﬂuorescence in situ hy-
bridization followed by immunoﬂuorescence in order to analyze the colocalization be-
tween speciﬁc PML isoforms, endogenous PML and telomeres.
3.1.3 Material and Methods
3.1.3.1 Plasmids
GFP-expression constructs (GFP-tagged PML isoforms 1 to 6) were provided by Prof.
Dr. Peter Hemmerich (Fritz-Lipmann-Institut Jena)
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3.1.3.2 Cell culture and transfection
U2OS and HeLa cells were obtained from the American Tissue Cultured Collection
(ATCC) and the ﬁbroblast cell lines VH7, were provided by Prof. Dr. P. Boukamp
(DKFZ, Heidelberg, Germany). All cell lines were cultured in Dulbecco's modiﬁed Ea-
gle's medium (DMEM) supplemented with 10% fetal calf serum in a 5% CO2 atmosphere
at 37°C. 1-2 day before transfection, cells were seeded on glass slides and transfected with
plasmid DNA by using FuGENE HD Transfection reagent (Roche, Basel, Switzerland)
according to the manufacturer's protocol. Cells were ﬁxed at diﬀerent time points. Al-
ternatively, cells were also transfected with Amaxa's Nucleofector Reagent according to
the manufacturer's protocol. Cells, transfected with AMAXA, were seeded and cultured
on glass slides after transfection and were ﬁxed at diﬀerent time points.
3.1.3.3 Western blots
Cellular fractionation was achieved by following the manufactures protocol with slight
modiﬁcations (Calbiochem / Merck Protein Fractionation Kit subcellular). Whole-cell
extracts, produced from the cultured cell lines and nuclear proteins were separated
by SDS-PAGE and transferred to the Immobilon(TM) -P-PVDF membrane (Millipore,
Schwalbach). The membrane was ﬁrst incubated with primary antibodies (PBS + 1%
serum) and then with a secondary HRP-conjugated anti-mouse IgG (Amersham Bio-
science, Freiburg, dilution 1:10000). Signals were detected using ECL Western Blot
detection Kit (Amersham Bioscience, Freiburg). Anti PML monoclonal mouse antibody
was from Linaris (PG-M3) and beta-actin antibody from Biozol.
3.1.3.4 Combined FISH with immunoﬂuorescence and microscopy
The PML nuclear bodies (for all isoforms) were detected by immunolocalization of PML
(PG-M3, mouse monoclonal, Linaris; dilution 1:200). The secondary antibody used as
reporter were tagged with FITC (Linaris, Germany; dilution 1:200) or Cy5 (Dianova,
dilution 1:200). The telomeres were revealed by a Cy3-labeled (CCCTAA)3 peptide
nucleic acid (PNA) probe (Dako, Dennmark). For combined telomere-FISH and PML
immunoﬂuorescence, cells were ﬁxed on glass slides with 3.7% formaldehyde (freshly pre-
pared, from 37% formaldehyde, J.T.Baker) in PBS (phosphate-buﬀered saline). After
ﬁxation the specimens were washed in PBS. Samples were then dehydrated by series of
ethanol (70%, 90%, 100%) each for 2 min incubation time and brieﬂy air dried. There-
after, 8µm of Cy3-labeled PNA probe were added and then denatured for 3 min at 80°C.
After hybridization for 2h at room temperature, the slides were washed several times
at room temperature with 70% formamide/10 mM Tris-HCL, pH 7.2 (25min), PBS (30
sec), 0.1xSSC for 5min at 65°C, and PBS containing 0.05% Tween-20 (2 x 5 min at room
temperature). After telomere-FISH the specimens were permeablized by incubation with
0.02% Triton X-100 (Sigma) in PBS for three minutes at room temperature. Then a
protein block was applied by incubation with 4% goat serum in PBS for 10 minutes.
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Antibodies, diluted in PBS containing 1% goat serum, were incubated for 30 minutes
at 37°C for the primary antibody and at room temperature for the secondary antibody.
Each antibody incubation was followed by three washes with PBS. Finally slides were
covered by 1 drop of anitfade solution (VectaSield, Linaris) containing 4,6-Diamidino-
2phenylindole (DAPI). 3D ﬂuorescence signals were detected in Z-stacks of about 10 to
30 frames with 0.28 µm spacing by confocal laser scanning microscopy (TCS SP5/SP2
Leica Microsystems, Germany) Images were processed using MacBiophotonics ImageJ
and subsequently exported and saved as JPEG ﬁles.
3.1.3.5 Quantiﬁcation of colocalization in three/four-channel 3D microscopy
images
For automated image analysis a program called CellSegmentation was used, which was
especially designed for this approach. (see chapter 2.2). In brief: To segment the
DAPI-stained cell nuclei in the third channel, we applied 3D median and Gaussian
ﬁlters for noise reduction with subsequent Otsu thresholding for segmentation of nuclei
and non-nuclei compartments. To detect structures such as telomere- and PML-spots,
coarse center positions of spot were determined by detection of intensity maxima. In
the next step, each detected spot candidate is quantiﬁed by the 3D intensity proﬁle
with an underlying Gaussian function. To determine colocalizations between telomeres
and endogenous PML, we utilized the geometry of the structures based on the ﬁtting
results, i.e. 3D position, 3D orientation and 3D shape. A colocalization was deﬁned as an
(partial) overlap of two or more structures from the diﬀerent channels using the geometry
of these structures. Due to the geometric representation of those structures with sub-
voxel resolution we were able to diﬀerentiate between diﬀerent types of colocalization
(see chapter 2.2).
3.1.3.6 Immunoﬂuorescence with endogenous PML-isoforms
The endogenous PML-isoforms are kindly provided by Hugues de Thé (Centre National
de la Recherche Scientiﬁque UMR7151, Equipe Labellisée par La Ligne Contre le Cancer,
Paris Cedex, France). For more details see Condemine et al. (2006).
The PML nuclear bodies of the diﬀerent isoforms (1, 2, 4 and 5) were detected by
immunolocalization of the endogenous PML isoforms (Condemine et al. 2006) (dilution
1:200). The secondary antibody used as a reporter were tagged with FITC (Linaris,
Germany; dilution 1:200). U2OS cell lines were ﬁxed on glass slides with 3.7% formalde-
hyde (freshly prepared, J.T.Baker) in PBS (phosphate-buﬀered saline). After ﬁxation
the specimens were washed in PBS. Then specimens were permeabilized by incubation
with 0.02% Triton X-100 (Sigma) in PBS for three minutes at room temperature. Then
a protein block was applied by incubation with 4% goat serum in PBS for 10 minutes.
Antibodies, diluted in PBS containing 1% goat serum, were incubated for 30 minutes
at 37°C for the primary antibody and at room temperature for the secondary antibody.
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Each antibody incubation was followed by three washes with PBS. Finally slides were
covered by 1 drop of anitfade solution (VectaSield, Linaris) containing 4,6-Diamidino-
2phenylindole (DAPI). 3D ﬂuorescence signals were detected in Z-stacks of about 10 to
30 frames with 0.28µm spacing by confocal laser scanning microscopy (TCS SP2 Leica
Microsystems, Germany)
3.1.4 Results
3.1.4.1 Western-blot analysis
To study the abundance distribution of the various PML isoforms in diﬀerent cell lines
(HeLa, U2OS and VH7), in relation to telomere maintenance mechanisms, we performed
Western blot analysis. The PG-M3 PML antibody (recognized all PML isoforms) reveals
diﬀerent PML isoforms proteins in the range from 45 kDa to 100 kDa. To avoid false
interpretation of the abundance of individual endogenous PML splicing variants, a better
approach would be theoretically to achieve western blots for each individual PML isoform.
The results of western blot by nuclear extraction, instead of whole cell extracts, shows
similar expression patterns of the PML isoforms in the diﬀerent cell lines.
3.1.4.2 GFP-tagged PML isoforms
The six nuclear isoforms of the PML protein result from alternative splicing of exon 7
to exon 9. All six isoforms were transfected as GFP-tagged fusionproteins to study if
any PML-Isoform colocalizes preferentially to the telomeres. GFP-tagged PML isoforms
were ﬁrst transiently transfected to U2OS using two diﬀerent transfection methods in
order to investigate which one is more eﬃcient. We investigated the cell lines 24h, 48h
and 72h hours after transfection. At time point 72h after transfection by AMAXA,
we were able to observe an expression pattern of all PML isoforms (except for isoform
2, which was not working in any experiment). Suboptimal expression patterns (72h
after transfection) were detected in cells transfected by FuGENE HD (data not shown).
Therefore, in all further experiments, cells were transfected by AMAXA and investigated
at time point 72h. Investigations at the late time point (72h), are based on the fact,
that PML number and size increases in response to cellular stress, which is given at the
time of transfection.
We studied U2OS transfected cells by the given GFP-construct, followed by telomere
FISH with subsequent immunoﬂuorescence (PG-M3 PML antibody). The goal was to
investigate the colocalization events between the diﬀerent PML isoforms, telomere signals
and endogenous PML antibody (recognizing all PML isoforms). Our results showed the
possibility to combine the transfection protocol for the GFP-constructs with subsequent
telomere-FISH, as shown in Figure 3.1, followed by immunoﬂuorescence as shown in
Figure 3.2.
To study whether any PML isoform colocalizes preferentially to the telomeres, we also
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Figure 3.1: U2OS cell lines were transfected with GFP-tagged PML isoforms 1-6 (green)
and subsequent telomere-FISH (red), nuclei stained with 4'6-diamidino-2-phenylindole
(DAPI, in blue). a) PML isoform 1, 72h after transfection b) PML isoform 2, 72h after transfection
(not working in any experiment, for not known reasons); c) PML isoform 3, 72h after transfection;d)
PML isoform 4, 72h after transfection; e) PML isoform 5, 72h after transfection; f) PML isoform 6,
72h after transfection. Images have been done by three-channel 3D microscopy (Maximum intensity
projection).
Figure 3.2: Four-channel 3D microscopy images of GFP-tagged PML isoform 4, combined
with telomere-FISH and immunoﬂuorescence of endogenous PML U2OS cells were transfected
with the GFP-tagged PML isoform 5 by AMAXA and ﬁxed after 72h. a) PML isoform 4 (green) and
PML Antibody Cy5 (red); b) PML antibody (green) and telomere (red); c) PML isoform 4 (green) and
telomere (red). Images have been done by four-channel 3D microscopy (DNA content stained by DAPI
in blue)
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Figure 3.3: Automatic quantiﬁcation of a four-channel 3D microscopy image with enlarged
section framed in red. U2OS cells were transfected with the GFP-tagged PML isoform 1, combined
by telomere-FISH and immunoﬂuorescence of endogenous PML. In the enlarged ﬁgures (framed in red),
quantiﬁed spots are marked by the black dots a) DAPI channel with nuclear segmentation; b) GFP-
tagged isoform 5; c) telomere-signals. d) endogenous PML spots (nucleus stained with DAPI shown in
white)
Table 3.1: Analyzed colocalization in a four-channel 3D ﬂuorescence microscopy image
colocalization classes* between telomeres and
endogenous PML
between telomeres and
GFP-tagged isoform
between endogenous
PML and GFP-tagged
isoform
colocalization class1* 0 0 0
colocalization class2* 0 0 0
colocalization class3* 25 15 6
colocalization class4* 0 2 4
colocalization class5* 0 9 0
colocalization class6* 0 0 0
*for more details see chapter 2.2
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Figure 3.4: Expression of GFP-tagged isoform 5 (green) varies between individual nuclei,
Transfection of the ALT positive cell lines U2OS with GFP-tagged isoform 5 (green) as example for
diﬀerent expression patterns. a) Moderate GFP expression of PML isoform 5 ; b) high GFP expression
of PML isoform 5 with aggregate-like structures (Counter staining with DAPI shown in blue)
expanded our program CellSegmention from a three-channel into a multi (four)- channel
quantiﬁcation of 3D microscopy images (three directions: x, y, z, and four channels:
ch1 for , ch2, ch3, ch4 for PML antibody, telomeres, GFP-tagged isoform and DAPI,
respectively). Thus, we were able to automatically quantify the diﬀerent colocalizations
in four-channel 3D microscopy images between PML isoforms, telomeres and endogenous
PML in the segmented DAPI (nucleus) channel. Results are shown in Figure 3.3 and
Table 3.1. The fact, that the expression patterns varied among individual nuclei, as
shown for the GFP-tagged isoform 5 (Figure 3.4), could lead to a misinterpretation of
the colocalization results and their relevance.
3.1.4.3 Immunoﬂuorescence of endogenous PML-isoforms
In order to validate carefully our studies which are performed under conditions of GFP-
tagged PML isoforms overexpression, we used the endogenous PML isoforms 1,2,4 and 5.
Results by immunoﬂuorescence with the diﬀerent PML isoforms are shown in Figure 3.5.
Isoform 1 and 2 were showing a good expression pattern in the nuclei with nearly no
background. PML isoform 4 and 5 show unspeciﬁc foci with a strong background, which
made it impractical to use these antibodies for further experiments. Nevertheless, we
were able to acquire images (stacks) for both protocols (Figure 3.6) to study possible
diﬀerences between endogenous PML isoforms (size and number) in non-transfected cells,
and GFP-tagged PML isoforms, which are more and less overexpressed in the nucleus.
First results showed that low expression levels only refer to endogenous PML bodies
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Figure 3.5: Immunoﬂuorescence in U2OS cell lines of endogenous PML-isoforms, Immunoﬂu-
orescence of the endogenous PML isoforms 1,2,4 and 5 in the ALT positive cell lines U2OS . a) endoge-
nous PML isoform 1 with speciﬁc protein expression pattern; b) endogenous PML isoform 2 with
speciﬁc protein expression pattern; c) endogenous PML isoform 4; protein expression pattern with a
strong background d) endogenous PML isoform 5 with strong background and non-speciﬁc expression
pattern (nucleus is revealed by 4'6-diamidino-2-phenylindole shown in blue)
and those of endogenous PML isoforms in non-transfected cells. An example of a low
expression pattern of GFP-tagged PML isoforms is shown in Figure 3.6 and for the
diﬀerent expression levels in Figure 3.4.
3.1.5 Concluding remarks and further perspectives
To understand the cellular function of PML NBs, studies have focused primarily on the
identiﬁcation of proteins that localized to these structures. Less is known about the
relationship between the PML splice variants and their potential diﬀerential regulation.
Furthermore, it has been shown, that diﬀerent PML isoforms did not localize to PML
NBs to the same extent. Kinetic studies showed that many PML isoforms are exchanged
fast between a individual nuclear body and the nucleoplasm (Bernardi and Pandolﬁ
2007).
Our hypothesis was, that speciﬁc PML isoforms are functionally relevant for the ALT
mechanism and therefore for the formation of ALT-associated PML bodies. As such, we
ﬁrst measured the PML protein expression pattern by Western blot analysis of extracts
from telomerase positive and ALT-positive cell lines. Our data showed no signiﬁcant
diﬀerences in the PML expression levels of the diﬀerent cell lines. This was due to the
diﬃculties in the precise characterization of the diﬀerent PML isoforms, which ranged
from about 100 kDa to 40 kDa. Therefore antibodies of all speciﬁc endogenous PML
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Figure 3.6: Comparison of GFP-tagged PML isoforms 1,2,4 and 5 (all with low GFP-
expression level) and immunoﬂuorescence of endogenous PML isoforms in ALT positive
cell lines (U2OS), a-d) GFP-tagged PML isoforms (green); a) GFP-tagged PML isoform 1, b) GFP-
tagged PML isoform 2; c) GFP-tagged PML isoform 4; d) GFP-tagged PML isoform 5 e-h) Immunoﬂu-
orescence of the endogenous PML isoforms 1,2,4 and 5; e) endogenous PML isoform 1; f) endogenous
PML isoform 2; g) endogenous PML isoform 4; h) endogenous PML isoform 5 (nucleus is stained by
4'6-diamidino-2-phenylindole shown in blue)
isoforms would be of great beneﬁt for further work in this ﬁeld.
Experiments by GFP-tagged PML isoform overexpression in the ALT positive cell line
U2OS showed indeed the possibility of combining the protocol of transfection, telomere-
FISH and immunoﬂuorescence, which were used to investigate whether any PML isoform
preferentially localizes to the telomeres. From our data we cannot conclude that spe-
ciﬁc PML isforms colocalizes preferentially to telomeres. Nevertheless, some important
questions remain to be answered: We do not know, how the cellular stress due to the
transfection protocol inﬂuences the size and amount of the PML NBs. Further it is not
known whether the overexpression of one PML isoform suppresses the expression of all
other PML isoforms or even the PML NBs itself. A better approach could be to knock
down one isoform to see if ALT positive cell lines still assemble ALT-associated PML
bodies.
In the literature, the evidence that not all PML nuclear bodies are composed equally is
described. For example, Muratani et al. (2002) has shown that PML NBs have diﬀerent
motilities. Further, often just a few PML NBs per cell are found to localize with proteins,
other nuclear organelles or chromatin regions. Nevertheless, for future investigations of
the PML isoforms and their function, it would be of great beneﬁt to generate isoform
speciﬁc PML antibodies, which would not only allow a look into the function of speciﬁc
PML isoforms but would also allow the study of the structure of PML nuclear bodies.
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In the last two decades much has been done in understanding the process of tumorigene-
sis. The role of genomic instability has gained cumulative attention in the last decade due
to its evident role in malignant transformation. The most common genetic alterations
occurring in tumorigeneses are seen in regulatory genes involved in cell cycle progres-
sion and arrest. Although cancers are quite diverse, with a large range of heterogeneity
amongst tumors in diﬀerent tissues, there are some characteristics which all tumors have
in common. These properties include unlimited replicative potential and prevalent in-
stability, both of which are described as telomeric dysfunction in Figure 4.1. Unlimited
replicative potential is a necessary step in long-term tumor growth and therefore, for
the pathogenesis of cancer. Consequently, telomere lengthening by the activation of
telomere maintenance mechanisms is discussed as a contributor to tumor progression
as they characterize most malignancies. Recent studies have aimed at investigating the
roles of ALT and telomerase in tumorigenesis to develop strategies that will improve the
treatment of malignancies such as sarcomas. Regarding the response to chemotherapy,
sarcomas range from histological subtypes that are very responsive to chemotherapy, to
subtypes that are quite resistant (Patel et al. 1997). Telomere maintenance mechanisms
as a target treatment to individual sarcomas are discussed as an alternative approach.
One ﬁrst step in this study was to determine the frequency distribution of diﬀer-
ent subgroups of the telomere maintenance mechanism in soft tissue sarcoma, such as
leiomyosarcoma, malignant ﬁbrous histiocytoma, malignant peripheral nerve sheath tu-
mors, synovial sarcoma and liposarcomas (pleomorphic, dediﬀerentiated, myxoid round
cell). Telomerase-activity was detected by TRAP-assay. For the detection of markers for
ALT, we ﬁrst investigated diﬀerent telomere length distributions in diﬀerent subgroups
of soft tissue sarcoma by Southern blot analysis. Initial results showed that some of the
investigated tumors exhibited exceptionally long telomeres. Although Southern blotting
turned out to be a robust method to determine the telomere length, we were not able to
analyze the frequency distribution of the diﬀerent telomere sizes. Therefore, we estab-
lished a combined telomere-FISH and PML immunoﬂuorescent technique in order to get
a direct impression about telomere size within the nuclei. Additionally, with this method
it is possible to detect a second marker of ALT which is referred to as ALT-associated
PML nuclear bodies. We applied this method and TRAP analysis to more than 120
samples of frozen tumor sections, 18 non-tumor sections and several cell lines exhibit-
ing diﬀerent telomere maintenance mechanism. A confocal laser scanning microscope
was used to obtain images from three independent ﬁelds. To analyze these 3D images
(stacks) with respect to markers of ALT, we designed in cooperation with Stefan Wörz
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Figure 4.1: Telomeric dysfunction and its possible impact Both, unlimited replicative potential
and widespread instability might be partly explained by telomeric dysfunction and is discussed in
tumorigenesis.
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(Dep. Bioinformatics and Functional Genomics, Biomedical Computer Version Group,
University of Heidelberg), a program for fully automated detection of PML NBs, and
measured telomere signals (resembling spots) of normal size and those exhibiting excep-
tionally large spots. To prevent signal detection outside the nucleus, we performed a
nuclear segmentation of the DAPI channel using the same analysis program. Therefore,
we were able to successfully capture more than 500 images (stacks) (see chapter 2.2). Our
data, analyzed with this program, revealed that even non-tumor samples and normal
human ﬁbroblasts showed APBs, whereas heterogeneous telomere spot distribution seem
to exclusively arise in tumor samples (see chapter 2.1). Further studies of the protein
level of the individual PML isoforms, might help to understand more about the function
of APBs. It may be that diﬀerent speciﬁc PML isoforms are functional relevant for the
assembling of APBs in case this structures are induced by diﬀerent cellular processes
besides ALT.
For a better understanding of the ALT-mechanism and its markers, it was very impor-
tant to develop this fully automated program. The detailed evaluation of markers for
ALT was possible due to the program.This program has impressively shown, that some
spots especially colocalization signals, are often diﬃcult to detect, as they are hardly
visible due to diﬀering intensities. Furthermore, analysis in 3D is very important, as
overlays of maximum intensity projections may lead to artifacts. For the future, such
programs will allow to investigate greater amounts of samples, not only for ALT, but for
other markers that appear as foci in the cell or even more in the cell nucleus.
To better understand telomere maintenance mechanism in more detail, we studied all
corresponding markers. Therefore, we discriminated not only between no and positive
telomerase activity but between diﬀerent expression levels. Even for the markers of ALT
we discriminated between diﬀerent amounts of APBs and very large telomeres. Having
distinguished between the occurrences of these diﬀerent levels of markers for TMM, we
were able to show that there are important diﬀerences. Analysis by CGH revealed that
some of the altered loci are conversely changed. For example, whereas on chromosome
1p13 losses are more frequent for tumors expressing high telomerase activity, tumors
with low or no expression levels more commonly have in the same loci gains. Such
diﬀerences might have important implication in the regulation of the expression level of
telomerase. Moreover, markers for ALT are on the same loci (1p13) also gained. We
conclude that this might be a strong indication for tumors exhibiting both telomere
maintenance mechanisms (see chapter 2.1). Such ﬁndings were only possible because
we discriminated in more detail among diﬀerent levels of the markers for ALT and
telomerase activity.
This study raises a number of issues that should be addressed in the future. For further
evaluation of the frequency distribution of TMM in tumors, it is important that there is
discrimination between diﬀerent levels of telomerase activity und markers for ALT. The
ﬁnding of APBs also in non-tumor-samples might be an indication that APBs could be
induced by diﬀerent cellular processes besides ALT. This has to be conﬁrmed by further
studies. Nevertheless, alternative markers for ALT are needed, as we do not know how
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tight APBs are linked to the ALT-mechanism. Even very large telomeres are discussed
in some publications as telomeric aggregates. Both seem to be totally diﬀerent events,
whereas large telomeres are a strong indication of ALT, the role of telomeric aggregates
is not fully understood. The data analyzed by CGH are also of major interest, as they
revealed a number of loci that might be involved in the regulation of both telomerase
expression and ALT. In summary, our results may have important implications for the
development of new strategies for anti-cancer therapies.
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